<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21647425</article-id><article-id pub-id-type="pmc">3102053</article-id><article-id pub-id-type="publisher-id">PONE-D-11-02253</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0019857</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Cardiovascular</subject><subj-group><subject>Cardiovascular Pharmacology</subject><subject>Coronary Artery Disease</subject><subject>Hypertension</subject><subject>Stroke</subject></subj-group></subj-group><subj-group><subject>Clinical Research Design</subject><subj-group><subject>Clinical Trials</subject></subj-group></subj-group><subj-group><subject>Drugs and Devices</subject><subj-group><subject>Adverse Reactions</subject><subject>Cardiovascular Pharmacology</subject></subj-group></subj-group><subj-group><subject>Global Health</subject></subj-group><subj-group><subject>Public Health</subject><subj-group><subject>Preventive Medicine</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>An International Randomised Placebo-Controlled Trial of a
Four-Component Combination Pill (&#x0201c;Polypill&#x0201d;) in People with Raised
Cardiovascular Risk</article-title><alt-title alt-title-type="running-head">Can a Polypill Safely Halve Cardiovascular
Risk?</alt-title></title-group><contrib-group><contrib contrib-type="author"><collab>PILL
Collaborative Group</collab><xref ref-type="author-notes" rid="fn1">
<sup>&#x000b6;</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>&#x0002a;</sup>
</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Wright</surname><given-names>James M.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">University of British Columbia, Canada</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>arodgers@georgeinstitute.org</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: AR AP OB MB RG DG RJ BN JN NP NR PR
SR ST SV. Performed the experiments: AR AP OB MB RG DG RJ BN JN NP NR PR SR
ST SV. Analyzed the data: SV. Wrote the paper: AR AP OB MB RG DG RJ BN JN NP
NR PR SR ST SV.</p></fn><fn id="fn1" fn-type="other"><p>&#x000b6; For a list of members please see the Acknowledgments.</p></fn></author-notes><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>25</day><month>5</month><year>2011</year></pub-date><volume>6</volume><issue>5</issue><elocation-id>e19857</elocation-id><history><date date-type="received"><day>30</day><month>1</month><year>2011</year></date><date date-type="accepted"><day>4</day><month>4</month><year>2011</year></date></history><permissions><copyright-statement>Rodgers et al.</copyright-statement><copyright-year>2011</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Background</title><p>There has been widespread interest in the potential of combination
cardiovascular medications containing aspirin and agents to lower blood
pressure and cholesterol (&#x02018;polypills&#x02019;) to reduce cardiovascular
disease. However, no reliable placebo-controlled data are available on both
efficacy and tolerability.</p></sec><sec><title>Methods</title><p>We conducted a randomised, double-blind placebo-controlled trial of a
polypill (containing aspirin 75 mg, lisinopril 10 mg, hydrochlorothiazide
12.5 mg and simvastatin 20 mg) in 378 individuals without an indication for
any component of the polypill, but who had an estimated 5-year
cardiovascular disease risk over 7.5&#x00025;. The primary outcomes were
systolic blood pressure (SBP), LDL-cholesterol and tolerability (proportion
discontinued randomised therapy) at 12 weeks follow-up.</p></sec><sec><title>Findings</title><p>At baseline, mean BP was 134/81 mmHg and mean LDL-cholesterol was 3.7 mmol/L.
Over 12 weeks, polypill treatment reduced SBP by 9.9 (95&#x00025; CI: 7.7 to
12.1) mmHg and LDL-cholesterol by 0.8 (95&#x00025; CI 0.6 to 0.9) mmol/L. The
discontinuation rates in the polypill group compared to placebo were
23&#x00025; vs 18&#x00025; (RR 1.33, 95&#x00025; CI 0.89 to 2.00,
p&#x0200a;=&#x0200a;0.2). There was an excess of side effects known to
the component medicines (58&#x00025; vs 42&#x00025;,
p&#x0200a;=&#x0200a;0.001), which was mostly apparent within a few
weeks, and usually did not warrant cessation of trial treatment.</p></sec><sec><title>Conclusions</title><p>This polypill achieved sizeable reductions in SBP and LDL-cholesterol but
caused side effects in about 1 in 6 people. The halving in predicted
cardiovascular risk is moderately lower than previous estimates and the side
effect rate is moderately higher. Nonetheless, substantial net benefits
would be expected among patients at high risk.</p></sec><sec><title>Trial Registration</title><p>Australian New Zealand Clinical Trials Registry <ext-link ext-link-type="uri" xlink:href="http://www.anzctr.org.au/trial_view.aspx?ID=1378">ACTRN12607000099426</ext-link>
</p></sec></abstract><counts><page-count count="11"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>In 2001, the World Health Organisation and The Wellcome Trust convened a meeting of
experts to discuss evidence-based and affordable interventions for non-communicable
diseases.<xref rid="pone.0019857-World1" ref-type="bibr">[1]</xref> A
major impetus for the meeting was the potential of fixed-dose combination pills
containing aspirin, statin and blood pressure lowering agents, noting &#x0201c;the use
of a single pill could well encourage patients to adhere to treatment as well as
seriously reduce the cost of the drugs.&#x0201d; A programme of research was outlined,
including stability and bio-availability testing followed by assessment of
short-term effects on blood pressure, cholesterol, platelet aggregation, safety and
side effects, ideally including developing country participants. In 2002, the WHO
Annual Report outlined the substantial potential public health impact and
cost-effectiveness of scaling up access to combination treatment.<xref rid="pone.0019857-World2" ref-type="bibr">[2]</xref> An editorial that
year also noted that a four component combination pill would be expected to reduce
cardiovascular risk by about 75&#x00025; among people with vascular disease.<xref rid="pone.0019857-Yusuf1" ref-type="bibr">[3]</xref> In 2003 the first
full exposition of the scientific evidence for cardiovascular combination pills was
published in the medical literature.<xref rid="pone.0019857-Law1" ref-type="bibr">[4]</xref>, <xref rid="pone.0019857-Law2" ref-type="bibr">[5]</xref>, <xref rid="pone.0019857-Wald1" ref-type="bibr">[6]</xref>, <xref rid="pone.0019857-Wald2" ref-type="bibr">[7]</xref> The &#x02018;polypill&#x02019; term was coined and gained
widespread attention, in large part due to the recommendation to treat everyone aged
over 55 years in developed countries. The proposal to target treatments based on age
alone has been highly polarizing. An alternate approach, now recommended by major
cross-disciplinary guidelines<xref rid="pone.0019857-Fourth1" ref-type="bibr">[8]</xref>, <xref rid="pone.0019857-British1" ref-type="bibr">[9]</xref>, <xref rid="pone.0019857-The1" ref-type="bibr">[10]</xref>, <xref rid="pone.0019857-New1" ref-type="bibr">[11]</xref> and the European Medicines Agency (EMA),<xref rid="pone.0019857-European1" ref-type="bibr">[12]</xref> is to target
treatments principally on the basis of global cardiovascular risk. As noted by the
EMA<xref rid="pone.0019857-European1" ref-type="bibr">[12]</xref>
&#x0201c;the terms primary/secondary prevention have yielded their place for a more
comprehensive strategy aimed at treating patients at high risk of cardiovascular
disease&#x02026;current therapeutic strategies are aimed at identifying global
cardiovascular disease risk in an individual and treating all risk factors. Global
risk intervention, rather than single risk modification is the standard of
care&#x0201d;.</p><p>We therefore set out to conduct the trial recommended by the meeting of the WHO and
The Wellcome Trust, assessing short-term efficacy and side effects, among people at
raised global cardiovascular risk. The trial aimed to assess the full effects of
polypill treatment compared to placebo. Such information would be relevant to
research among people with raised cardiovascular risk (many of whom are not
currently treated as they do not have &#x02018;hypertension&#x02019; or
&#x02018;dyslipidaemia&#x02019;) and we planned this initiative as a necessary first
step before starting a large long-term trial in this population. The trial was also
planned to inform research and treatment in people with established vascular
disease, since the risk factor reductions would be generalisable but use of placebo
is not appropriate in this group.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><p>The protocol for this trial and supporting CONSORT checklist are available as
supporting information; see <xref ref-type="supplementary-material" rid="pone.0019857.s002">Checklist S1</xref> and <xref ref-type="supplementary-material" rid="pone.0019857.s001">Protocol
S1</xref>.</p><p>We conducted a randomised controlled trial in seven countries &#x02013; Australia
(n&#x0200a;=&#x0200a;21), Brazil (n&#x0200a;=&#x0200a;8), India
(n&#x0200a;=&#x0200a;109), Netherlands (n&#x0200a;=&#x0200a;102), New
Zealand (n&#x0200a;=&#x0200a;12), United Kingdom (n&#x0200a;=&#x0200a;113)
and United States (n&#x0200a;=&#x0200a;13). Approval for the trial was obtained
from the institutional ethics committee of each centre and all participants provided
written informed consent. The trial is registered with the Australian New Zealand
Clinical Trials Registry (ACTRN 12607000099426).</p><sec id="s2a"><title>Participants</title><p>The key eligibility criteria were raised cardiovascular risk together with no
indication for or contraindication to treatment with component medicines in the
polypill. Individuals were included if they were adults (&#x02265;18 years) with a
cardiovascular disease (CVD) risk over 5 years of at least 7.5&#x00025;,
determined by the Framingham risk function<xref rid="pone.0019857-Anderson1" ref-type="bibr">[13]</xref> using data on age,
gender, blood pressure, total cholesterol, HDL cholesterol, diabetes status and
cigarette smoking status (left ventricular hypertrophy was assumed to be absent
for the purpose of CVD risk calculation). A value of 7.5&#x00025; on Framingham
function was chosen as half the threshold value above which all modalities are
recommended in the first set of guidelines based on absolute risk.<xref rid="pone.0019857-Jackson1" ref-type="bibr">[14]</xref> While
Framingham performs well in modern clinical practice after calibration<xref rid="pone.0019857-Riddell1" ref-type="bibr">[15]</xref> it is
nonetheless imperfect.<xref rid="pone.0019857-Using1" ref-type="bibr">[16]</xref> For example, it does not incorporate some risk
factors that have additional predictive value. Therefore, those with an
estimated 5-year risk of 5.0&#x02013; &#x0003c;7.5&#x00025; from the Framingham function
were also eligible if two or more additional risk factors were present: body
mass index (BMI) &#x0003e;30 kg/m<sup>2</sup>; waist circumference &#x0003e;102 cm in men
or &#x0003e;88 cm in women; heart rate &#x0003e;80 beats/min; fasting glucose 5.6&#x02013;
&#x0003c;7 mmol/L; triglycerides &#x0003e;1.7 mmol/L; family history of premature coronary
heart disease (CHD) or ischaemic stroke in a first degree male relative before
the age of 55 years or a first degree female relative before the age of 65
years; or glomerular filtration rate (GFR) &#x0003c;60 mL/min. Uniform definitions
were used for all centres. To be included, the participants had to have no
contraindication to treatment with low-dose aspirin, angiotensin-converting
enzyme (ACE) inhibitor, low-dose diuretic or statin; nor any indication or
recommendation under local guidance for treatment with any of these medicines.
The participating countries varied in their extent of risk factor
threshold-based (eg. hypertension treatment) or absolute risk-based treatment
practices. Therefore some participants had comparatively high risk factor levels
(but moderate absolute risk), while others had comparatively high absolute risk
(but moderate risk factor levels). Participants taking other antiplatelet, blood
pressure lowering or cholesterol lowering medicines were also excluded, as were
patients with diabetes mellitus or GFR &#x02264;30 ml/min/1.73 m<sup>2</sup>.</p></sec><sec id="s2b"><title>Randomisation, Allocation Concealment and Study Interventions</title><p>Eligible participants were randomised to the Red Heart Pill (RHP, a polypill
comprising a bilayered tablet containing aspirin 75 mg, lisinopril 10 mg,
hydrochlorothiazide 12.5 mg and simvastatin 20 mg) or an identical placebo, in a
1:1 ratio. Participants, research staff and and co-ordinating centre staff were
all blinded to the allocation. Study treatment was taken once a day in the
evening with food. There was no &#x02018;run-in&#x02019; period. Study treatments
were allocated using a central computer-based randomisation service at The
Clinical Trials Research Unit, University of Auckland, accessible by internet,
using a minimisation algorithm including age, sex and centre. Participants were
recruited from 17 October 2008 to 22 December 2009. Regulatory delays in
importing trial treatment were prolonged and recruitment was 22 participants
less than intended, since the study medication expiry date was reached.</p></sec><sec id="s2c"><title>Concomitant Interventions</title><p>The use of concomitant open-label therapy was allowed at the discretion of the
responsible clinician. Without the need to unblind, additional treatment with
open-label therapy was permitted &#x02013;75 mg aspirin; any beta-blocker, calcium
channel blocker, angiotensin receptor blocker or alpha-blocker; 10&#x02013;20 mg
lisinopril and/or 12.5 mg hydrochlorothiazide or 2.5 mg bendrofluazide;
10&#x02013;20 mg simvastatin &#x02013; if any of these treatments became indicated
during the trial. If there was a need for higher doses of aspirin, ACE
inhibitor, diuretic or simvastatin, these were provided as open label treatment
and the trial treatment was stopped. Open-label fibrate (with the exception of
gemfibrozil) could also be added, without the need to unblind or stop the trial
treatment, provided that appropriate monitoring for rhabdomyolysis was
instituted.</p></sec><sec id="s2d"><title>Study Procedures</title><p>Participants were seen at 2, 6 and 12 weeks after randomisation, with a
post-study follow-up appointment 4 weeks after the final 12-week visit. At study
visits, information on adherence to and tolerability of study treatments, blood
pressure, lipids and occurrence of adverse events was obtained. Blood pressure
was recorded as the mean of two measurements made after the patient was rested
for at least 5 minutes in the seated position, using a standardised automated
sphygmomanometer that had been validated according to the protocol of the
Association for the Advancement of Medical Instrumentation (AAMI) or British
Hypertension Society, International protocol version. Lipid measurements were
undertaken at local laboratories holding ISO 15189 (2003 or later)
accreditation. The trial was co-ordinated by The Clinical Trials Research Unit,
at The University of Auckland which provided an internet based clinical trial
management system. An independent monitor completed bi- monthly site visits to
ensure the trial was conducted according to the protocol, good clinical practice
guidelines and relevant local regulatory requirements. All participants provided
informed consent.</p></sec><sec id="s2e"><title>Outcomes</title><p>The primary study outcomes were change in systolic blood pressure (SBP), change
in LDL-cholesterol and tolerability (proportion who withdrew from trial
treatment for any reason). Secondary outcomes were treatment adherence (&#x00025;
of prescribed treatment according to pill counts, with participants asked to
return all used blisters and unused trial treatment to study visits), diastolic
blood pressure, total cholesterol, HDL cholesterol, total cholesterol:HDL
cholesterol ratio, non-HDL cholesterol, triglycerides, frequency of
switching/adding open-label treatment and estimated effects on CVD risk.</p></sec><sec id="s2f"><title>Sample Size</title><p>It was estimated that 400 participants would provide 85&#x00025; power at
2p&#x0200a;=&#x0200a;0.05 to detect a 0.25 mmol/l difference in
LDL-cholesterol and 80&#x00025; power to detect a 4 mmHg difference in systolic
blood pressure between the intervention and control groups, assuming standard
deviations around the change from baseline levels of 0.8 mmol/l and 14 mmHg
respectively, and a 10&#x00025; absolute difference in tolerability. This sample
size would also provide a 95&#x00025; confidence interval width of about 6 mmHg
and 0.3 mmol/L for estimates of SBP and LDL-cholesterol reductions
respectively.</p></sec><sec id="s2g"><title>Statistical analysis</title><p>Primary analysis was by intention-to-treat. Means of changes in blood pressure
and lipid values from baseline to 12 weeks between polypill and placebo groups
were compared using a 2 sample t-test. Adjusted analyses were carried out by
including the stratification factors in an analysis of covariance regression
model with change in blood pressure and lipid variable as the dependent
variable. Last observation carried forward was used for missing data at 12
weeks, with a sensitivity analysis also based on repeated measures using a mixed
models approach to the analysis of covariance. The proportions that withdrew
from trial treatment (tolerability) at 12 weeks between polypill and placebo
groups were compared using the chi-squared test, with those without follow-up
information assumed to have stopped study treatment. It was determined after
trial completion that there had been mislabeling of a sequence of treatment
packs that affected 14 participants who received active treatment rather than
placebo. Therefore an additional sensitivity analysis was conducted excluding
these participants. All analyses were done using SAS [version
9.1.3].</p><p>Expected reductions in cardiovascular risk were estimated using data from
systematic reviews, which have shown that each medication class confers
approximately similar proportional reductions in cause-specific outcomes across
a wide range of patient populations, with no major differences between agents
(after accounting for the extent of risk factor reduction for SBP and LDL) and
even when event rates vary tenfold or more.<xref rid="pone.0019857-Law3" ref-type="bibr">[17]</xref>, <xref rid="pone.0019857-Blood1" ref-type="bibr">[18]</xref>, <xref rid="pone.0019857-Cholesterol1" ref-type="bibr">[19]</xref>, <xref rid="pone.0019857-Antithrombotic1" ref-type="bibr">[20]</xref>, <xref rid="pone.0019857-Law4" ref-type="bibr">[21]</xref> For example,
aspirin produces about a one-fifth reduction in CHD and ischaemic stroke risk in
&#x02018;primary&#x02019; and &#x02018;secondary&#x02019; prevention.<xref rid="pone.0019857-Antithrombotic1" ref-type="bibr">[20]</xref>
There is clear evidence that the proportional reductions in major outcomes
achieved with each treatment modality are approximately the same in the presence
or absence of other interventions<xref rid="pone.0019857-Law3" ref-type="bibr">[17]</xref>, <xref rid="pone.0019857-Cholesterol1" ref-type="bibr">[19]</xref>, <xref rid="pone.0019857-Antithrombotic1" ref-type="bibr">[20]</xref>, <xref rid="pone.0019857-Law5" ref-type="bibr">[22]</xref> (which is
expected given the lack of interaction between treatments in terms of risk
factor reduction<xref rid="pone.0019857-The2" ref-type="bibr">[23]</xref> and the epidemiology of blood pressure and
cholesterol joint effects<xref rid="pone.0019857-Asia1" ref-type="bibr">[24]</xref>, <xref rid="pone.0019857-ProspectiveStudies1" ref-type="bibr">[25]</xref>). Therefore,
the combined effects are best estimated by multiplying relative risks together,
after adjusting for the size of SBP and LDL-cholesterol reductions. Thus for
example, since 1 mmol/L LDL-cholesterol reduction, 10 mmHg SBP reduction and
aspirin each individually lower CHD risk by 42&#x00025;<xref rid="pone.0019857-Law2" ref-type="bibr">[5]</xref>, 22&#x00025;<xref rid="pone.0019857-Law3" ref-type="bibr">[17]</xref> and
20&#x00025;<xref rid="pone.0019857-Antithrombotic1" ref-type="bibr">[20]</xref> respectively (ie. RRs are 0.58, 0.78 and 0.80
respectively), the expected joint effects of a 0.5 mmol/L LDL-cholesterol
reduction, 5 mmHg SBP reduction and aspirin would be approximately a 46&#x00025;
lower CHD risk (since
0.58<sup>0.5/1.0</sup>&#x000d7;0.78<sup>5/10</sup>&#x000d7;0.80&#x0200a;=&#x0200a;0.54,
and (1&#x02212;0.54) &#x000d7;100&#x00025; &#x0200a;=&#x0200a;46&#x00025;).
Combining the proportional effects with data on current event rates (rather than
event rates in trials, which are often out of date and not representative),
provides the best estimates of expected absolute treatment effects.<xref rid="pone.0019857-Glasziou1" ref-type="bibr">[26]</xref>, <xref rid="pone.0019857-Jackson2" ref-type="bibr">[27]</xref>
</p></sec></sec><sec id="s3"><title>Results</title><p>A total of 378 participants were randomised into the study (<xref ref-type="fig" rid="pone-0019857-g001">Figure 1</xref>) from 17 October 2008 to 22 December
2009. At 12 weeks, vital status was available for 373 (98.7&#x00025;) of participants
and data on SBP and LDL-cholesterol levels were available for 338 (89.4&#x00025;).
There was good balance between randomised groups across a range of characteristics
at study entry (<xref ref-type="table" rid="pone-0019857-t001">Table 1</xref>). The
frequency distributions for age, SBP, LDL-cholesterol and estimated 5-year
cardiovascular risk are shown in <xref ref-type="fig" rid="pone-0019857-g002">Figure
2</xref>. As can be seen, most patients were aged between 50 and 70 years and
there was a wide range of baseline SBP and LDL-cholesterol levels; for example
according to JNC 7 criteria<xref rid="pone.0019857-Chobanian1" ref-type="bibr">[28]</xref> 33&#x00025; would be regarded as having
&#x02018;hypertension&#x02019; with SBP &#x0003e;140 mmHg, 52&#x00025;
&#x02018;pre-hypertension&#x02019; with SBP 120&#x02013;139, and 14&#x00025; having
&#x02018;normal&#x02019; blood pressure of SBP &#x0003c;120 mmHg. Overall 22&#x00025; of
participants had a 5-year cardiovascular risk of 5&#x02013;7.5&#x00025; by the
Framingham function (all of whom had two or more other risk factors, see <xref ref-type="sec" rid="s2">Methods</xref>), and 3&#x00025; had 5-year cardiovascular
risk over 20&#x00025; (ie. equivalent to the risk faced by those with previous
vascular disease events<xref rid="pone.0019857-Law6" ref-type="bibr">[29]</xref>).</p><fig id="pone-0019857-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0019857.g001</object-id><label>Figure 1</label><caption><title>CONSORT flow chart.</title><p>This figure shows the flow of patients through the trial according to the
criteria recommended in the CONSORT Guidelines.</p></caption><graphic xlink:href="pone.0019857.g001"/></fig><fig id="pone-0019857-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0019857.g002</object-id><label>Figure 2</label><caption><title>Baseline frequency distributions of age, LDL-cholesterol, SBP and 5-year
cardiovascular risk.</title><p>This figure shows the frequency distribution of participants according to
their baseline levels of age, LDL-cholesterol, SBP and 5-year cardiovascular
risk.</p></caption><graphic xlink:href="pone.0019857.g002"/></fig><table-wrap id="pone-0019857-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0019857.t001</object-id><label>Table 1</label><caption><title>Baseline characteristics.</title></caption><alternatives><graphic id="pone-0019857-t001-1" xlink:href="pone.0019857.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1">Red Heart
Pilln&#x0200a;=&#x0200a;189</td><td colspan="2" align="left" rowspan="1">Placebon&#x0200a;=&#x0200a;189</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic>Cardiovascular risk factors in Framingham score</italic>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age (yrs)</td><td align="left" rowspan="1" colspan="1">61.2</td><td align="left" rowspan="1" colspan="1">(7.2)</td><td align="left" rowspan="1" colspan="1">61.6</td><td align="left" rowspan="1" colspan="1">(7.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">153</td><td align="left" rowspan="1" colspan="1">(81&#x00025;)</td><td align="left" rowspan="1" colspan="1">152</td><td align="left" rowspan="1" colspan="1">(80&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood pressure (mmHg)</td><td align="left" rowspan="1" colspan="1">132/80</td><td align="left" rowspan="1" colspan="1">(13/9)</td><td align="left" rowspan="1" colspan="1">136/81</td><td align="left" rowspan="1" colspan="1">(14/9)</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL-cholesterol (mmol/L)</td><td align="left" rowspan="1" colspan="1">3.7</td><td align="left" rowspan="1" colspan="1">(0.9)</td><td align="left" rowspan="1" colspan="1">3.6</td><td align="left" rowspan="1" colspan="1">(0.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Total cholesterol (mmol/L)</td><td align="left" rowspan="1" colspan="1">5.6</td><td align="left" rowspan="1" colspan="1">(1.1)</td><td align="left" rowspan="1" colspan="1">5.4</td><td align="left" rowspan="1" colspan="1">(1.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL (mmol/L)</td><td align="left" rowspan="1" colspan="1">1.2</td><td align="left" rowspan="1" colspan="1">(0.3)</td><td align="left" rowspan="1" colspan="1">1.3</td><td align="left" rowspan="1" colspan="1">(0.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoker (or quit within the last year)</td><td align="left" rowspan="1" colspan="1">79</td><td align="left" rowspan="1" colspan="1">(42&#x00025;)</td><td align="left" rowspan="1" colspan="1">74</td><td align="left" rowspan="1" colspan="1">(39&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Other cardiovascular risk factors</italic>
<xref ref-type="table-fn" rid="nt102">&#x0002a;</xref>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index &#x0003e;30 kg/m<sup>2</sup>, waist
circumference &#x0003e;102 cm in men or &#x0003e;88 cm in women</td><td align="left" rowspan="1" colspan="1">88</td><td align="left" rowspan="1" colspan="1">(47&#x00025;)</td><td align="left" rowspan="1" colspan="1">90</td><td align="left" rowspan="1" colspan="1">(48&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart rate &#x0003e;80 beats/min</td><td align="left" rowspan="1" colspan="1">48</td><td align="left" rowspan="1" colspan="1">(25&#x00025;)</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">(24&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting glucose 5.6&#x02013; &#x0003c;7 mmol/L</td><td align="left" rowspan="1" colspan="1">55</td><td align="left" rowspan="1" colspan="1">(29&#x00025;)</td><td align="left" rowspan="1" colspan="1">60</td><td align="left" rowspan="1" colspan="1">(32&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Family history of premature coronary heart disease or
ischaemic stroke</td><td align="left" rowspan="1" colspan="1">87</td><td align="left" rowspan="1" colspan="1">(46&#x00025;)</td><td align="left" rowspan="1" colspan="1">77</td><td align="left" rowspan="1" colspan="1">(41&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglycerides &#x0003e;1.7 mmol/L</td><td align="left" rowspan="1" colspan="1">69</td><td align="left" rowspan="1" colspan="1">(37&#x00025;)</td><td align="left" rowspan="1" colspan="1">53</td><td align="left" rowspan="1" colspan="1">(28&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Glomerular filtration rate (GFR) &#x0003c;60 mL/min</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">(10&#x00025;)</td><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">(12&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">At least 2 of the above<xref ref-type="table-fn" rid="nt102">&#x0002a;</xref>
</td><td align="left" rowspan="1" colspan="1">120</td><td align="left" rowspan="1" colspan="1">(63&#x00025;)</td><td align="left" rowspan="1" colspan="1">117</td><td align="left" rowspan="1" colspan="1">(62&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Cardiovascular risk</italic>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">5-year cardiovascular risk - Framingham function</td><td align="left" rowspan="1" colspan="1">10&#x00025;</td><td align="left" rowspan="1" colspan="1">(4.1&#x00025;)</td><td align="left" rowspan="1" colspan="1">11&#x00025;</td><td align="left" rowspan="1" colspan="1">(4.5&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">10-yr fatal cardiovascular risk &#x02013; SCORE
function</td><td align="left" rowspan="1" colspan="1">4.3&#x00025;</td><td align="left" rowspan="1" colspan="1">(5.0&#x00025;)</td><td align="left" rowspan="1" colspan="1">4.9&#x00025;</td><td align="left" rowspan="1" colspan="1">(5.4&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Medications</italic>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Prescribed or over-the-counter medicines</td><td align="left" rowspan="1" colspan="1">59</td><td align="left" rowspan="1" colspan="1">(31&#x00025;)</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">(23&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Vitamin and/or mineral capsules/tablets</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">(23&#x00025;)</td><td align="left" rowspan="1" colspan="1">37</td><td align="left" rowspan="1" colspan="1">(20&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Other dietary supplements</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">(18&#x00025;)</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">(16&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Any other complementary or alternative medicine</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">(3&#x00025;)</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">(4&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Current lifestyle factors</italic>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Moderate physical exercise in last 7 days (mins)</td><td align="left" rowspan="1" colspan="1">211</td><td align="left" rowspan="1" colspan="1">(240)</td><td align="left" rowspan="1" colspan="1">256</td><td align="left" rowspan="1" colspan="1">(279)</td></tr><tr><td align="left" rowspan="1" colspan="1">Vigorous physical exercise in last 7 days (mins)</td><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">(104)</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">(49)</td></tr><tr><td align="left" rowspan="1" colspan="1">Formal exercise programme</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">(2&#x00025;)</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">(3&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Seeing a dietician or other nutritional counsellor or
on a weight control programme</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">(1&#x00025;)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">(1&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking cessation programme</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">(2&#x00025;)</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">(1&#x00025;)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Other</italic>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Currently drink alcohol once a week or more (on most
weeks for at least the last year)</td><td align="left" rowspan="1" colspan="1">132</td><td align="left" rowspan="1" colspan="1">(69&#x00025;)</td><td align="left" rowspan="1" colspan="1">142</td><td align="left" rowspan="1" colspan="1">(75&#x00025;)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>Data are mean (sd) or n (&#x00025;).</p></fn><fn id="nt102"><label/><p>&#x0002a;Participants with Framingham 5-yr CVD risk 5&#x02013;7.5&#x00025; were
eligible for the trial if they had at least two such factors.</p></fn></table-wrap-foot></table-wrap><sec id="s3a"><title>Effects on blood pressure and cholesterol levels</title><p>Over the duration of follow-up, SBP was reduced by an average of 9.9 (95&#x00025;
CI: 7.7 to 12.1) mmHg compared to the placebo group, while LDL-cholesterol was
reduced by an average of 0.8 (95&#x00025; CI: 0.6 to 0.9) mmol/L (both
p&#x0003c;0.0001, see <xref ref-type="fig" rid="pone-0019857-g003">Figure 3</xref>).
Treatment differences were achieved at two weeks and maintained throughout
follow-up. Overall effect estimates were not importantly altered by adjusted
analyses or by the exclusion of participants receiving mislabeled treatment
packs (SBP reduction 10.4, 95&#x00025; CI 8.1 to 12.7 mmHg and LDL-cholesterol
reduction 0.8, 95&#x00025; CI 0.7 to 0.9 mmol/L).</p><fig id="pone-0019857-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0019857.g003</object-id><label>Figure 3</label><caption><title>Blood pressure and LDL-cholesterol changes.</title><p>This figure shows the changes in blood pressure and LDL-cholesterol over
the 12 week trial period, according to active (dark line) or placebo
(grey line).</p></caption><graphic xlink:href="pone.0019857.g003"/></fig><p>There was also a reduction in DBP of 5.3 mmHg (95&#x00025; CI 3.9 to 6.7,
p&#x0003c;&#x0003c;0.001), in total cholesterol of 0.8 mmol/L (95&#x00025;CI,
0.7&#x02013;1.0, p&#x0003c;0.001) and in triglycerides of 0.2 mmol/L (95&#x00025;CI
0.1&#x02212;0.3, p&#x0200a;=&#x0200a;0.001). There was no clear effect on HDL
(0.02 mmol/L increase, 95&#x00025; CI &#x02212;0.04 to 0.04,
p&#x0200a;=&#x0200a;0.9).</p></sec><sec id="s3b"><title>Tolerability and side effects</title><p>Overall through the 12 weeks, 44 (23&#x00025;) in the polypill group compared to
33 (18&#x00025;) in the placebo group discontinued treatment (RR 1.33, 95&#x00025;
CI 0.89 to 2.00 p&#x0200a;=&#x0200a;0.2). Most discontinuations occurred
early: 29 (66&#x00025;) of the 44 discontinuations in the polypill group occurred
by week 6. The main reasons for discontinuation of trial treatment by randomised
group are shown in <xref ref-type="table" rid="pone-0019857-t002">Table
2</xref>.</p><table-wrap id="pone-0019857-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0019857.t002</object-id><label>Table 2</label><caption><title>Main reasons for stopping study treatment and side effects.</title></caption><alternatives><graphic id="pone-0019857-t002-2" xlink:href="pone.0019857.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="5" align="left" rowspan="1">Reported side effects of sufficient
severity to discontinue study treatment<xref ref-type="table-fn" rid="nt103">&#x0002a;</xref>
</td><td colspan="5" align="left" rowspan="1">Reported side effects not necessitating
discontinuation of study treatment</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1">Red Heart Pill</td><td colspan="2" align="left" rowspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">P-value</td><td colspan="2" align="left" rowspan="1">Red Heart Pill</td><td colspan="2" align="left" rowspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">P-value</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">n</td><td align="left" rowspan="1" colspan="1">&#x00025;</td><td align="left" rowspan="1" colspan="1">n</td><td align="left" rowspan="1" colspan="1">&#x00025;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">n</td><td align="left" rowspan="1" colspan="1">&#x00025;</td><td align="left" rowspan="1" colspan="1">n</td><td align="left" rowspan="1" colspan="1">&#x00025;</td><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Gastric irritation</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">3&#x00025;</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1&#x00025;</td><td align="left" rowspan="1" colspan="1">0.06</td><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">12&#x00025;</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">3&#x00025;</td><td align="left" rowspan="1" colspan="1">0.0005</td></tr><tr><td align="left" rowspan="1" colspan="1">Increased bleeding tendency</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0&#x00025;</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0&#x00025;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">2&#x00025;</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1&#x00025;</td><td align="left" rowspan="1" colspan="1">0.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Cough</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">2&#x00025;</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1&#x00025;</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">10&#x00025;</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">2&#x00025;</td><td align="left" rowspan="1" colspan="1">0.0002</td></tr><tr><td align="left" rowspan="1" colspan="1">Light headed/dizziness/hypotension</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">4&#x00025;</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1&#x00025;</td><td align="left" rowspan="1" colspan="1">0.09</td><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">15&#x00025;</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">4&#x00025;</td><td align="left" rowspan="1" colspan="1">0.0002</td></tr><tr><td align="left" rowspan="1" colspan="1">Muscle pain or weakness</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1&#x00025;</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1&#x00025;</td><td align="left" rowspan="1" colspan="1">0.6</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">7&#x00025;</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">7&#x00025;</td><td align="left" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" rowspan="1" colspan="1">Headache</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0&#x00025;</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0&#x00025;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">2&#x00025;</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">2&#x00025;</td><td align="left" rowspan="1" colspan="1">0.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Diarrhoea</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0&#x00025;</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0&#x00025;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">2&#x00025;</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">3&#x00025;</td><td align="left" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Fatigue</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">2&#x00025;</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1&#x00025;</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">7&#x00025;</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">5&#x00025;</td><td align="left" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Abdominal pain</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0&#x00025;</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0&#x00025;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">2&#x00025;</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1&#x00025;</td><td align="left" rowspan="1" colspan="1">0.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Constipation</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0&#x00025;</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0&#x00025;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">5&#x00025;</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">2&#x00025;</td><td align="left" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" rowspan="1" colspan="1">Flatulence</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0&#x00025;</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0&#x00025;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">3&#x00025;</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">3&#x00025;</td><td align="left" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Other side effect</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">6&#x00025;</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">6&#x00025;</td><td align="left" rowspan="1" colspan="1">0.8</td><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1">21&#x00025;</td><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">15&#x00025;</td><td align="left" rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" rowspan="1" colspan="1">Patient choice</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0&#x00025;</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">2&#x00025;</td><td align="left" rowspan="1" colspan="1">0.08</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Total<xref ref-type="table-fn" rid="nt104">&#x0002a;&#x0002a;</xref>
</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">18&#x00025;</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">13&#x00025;</td><td align="left" rowspan="1" colspan="1">0.2</td><td align="left" rowspan="1" colspan="1">81</td><td align="left" rowspan="1" colspan="1">43&#x00025;</td><td align="left" rowspan="1" colspan="1">59</td><td align="left" rowspan="1" colspan="1">31&#x00025;</td><td align="left" rowspan="1" colspan="1">0.003</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt103"><label/><p>&#x0002a;participants without relevant follow-up data at 12 weeks (10 vs
9) were assumed to have stopped treatment in the definition of
tolerability as the primary trial outcome, which was therefore 44
(23&#x00025;) vs 33 (18&#x00025;).</p></fn><fn id="nt104"><label/><p>&#x0002a;&#x0002a;for patients discontinuing treatment, the total is a direct
sum as data reflect the main reason for stopping for each patient.
For patients not discontinuing treatment, the total refers to the
number of people reporting one or more side effects.</p></fn></table-wrap-foot></table-wrap><p>A total of 110 (58&#x00025;) of the polypill group and 79 (42&#x00025;) of the
control group reported side effects (p&#x0200a;=&#x0200a;0.001). Most side
effects did not necessitate stopping treatment. The excesses were mainly
attributable to the well known side effects of aspirin [gastric irritation
and/or bleeding tendency occurring in 32 (17&#x00025;) of the polypill group and
11 (6&#x00025;) of the placebo group] and of ACE inhibitor-based blood
pressure lowering [cough and/or light headedness, dizziness or hypotension
occurring in 57 (30&#x00025;) of the polypill group and 20 (11&#x00025;) of the
placebo group]. Most side effects were apparent early on: at week 2, side
effects were reported by 41&#x00025; vs 26&#x00025; (77 vs 49 people), whereas
only 14&#x00025; vs 11&#x00025; (26 vs 20) reported new side effects in week 6 and
only 4&#x00025; vs 5&#x00025; (7 vs 10) reported new side effects at week 12. A
total of 353 participants answered the question &#x0201c;what trial treatment do
you think you have been taking?&#x0201d; at the end of follow-up. The answer was
correct for 79&#x00025; (139/177) of people allocated polypill and for 59&#x00025;
(104/176) of people allocated placebo (p&#x0003c;0.0001 for difference).</p><p>Eight serious adverse events were reported, four in each group (polypill group -
chest pain, newly diagnosed Type 2 diabetes, removal of wisdom teeth, syncope;
placebo group &#x02013; syncope, depression, transient ischaemic attack, hip
fracture). There were no deaths, major vascular events, major bleeds or episodes
of gastrointestinal ulceration.</p><p>Overall, the proportion of scheduled treatment taken according to self-reported
pill counts was 82&#x00025; for the polypill group and 86&#x00025; for the placebo
group (p&#x0200a;=&#x0200a;0.1). Open-label therapy was required
infrequently during follow-up: for blood pressure lowering (4 vs 3
participants), cholesterol lowering (0 vs 4) and antiplatelet therapy (2 vs
3).</p></sec><sec id="s3c"><title>Predicted effects on cardiovascular risk</title><p>The estimated effects on cardiovascular events and other major outcomes for those
continuing treatment long-term are shown in <xref ref-type="table" rid="pone-0019857-t003">Table 3</xref>. One would expect an approximate
60&#x00025; reduction in CHD and ischaemic stroke risk, little overall effect on
haemorrhagic stroke risk (the beneficial effects of blood pressure lowering
balancing out the adverse effects of aspirin) and a 50&#x00025; increase in the
risk of extra-cranial bleeding. The net effects of such treatment on any major
outcome thus importantly depend on the event rates of each component outcome. In
a patient group at similar risk to the average in this trial one would expect
more than a halving in CVD events and about a halving in any major event
(stroke, CHD or major bleed). Over 5 years of treatment, about 1 in 18 would
benefit in terms of avoiding a major event, with the large majority of the net
benefit due to the SBP and LDL-reduction. Among untreated individuals with a
history of coronary artery disease, event rates are higher, particularly for CHD
and ischaemic stroke.<xref rid="pone.0019857-Law6" ref-type="bibr">[29]</xref>, <xref rid="pone.0019857-Steg1" ref-type="bibr">[30]</xref> Hence compared to a lower-risk population, the
proportional reductions for the composite of any major event are a little
greater and the absolute benefits are much greater, being of clear clinical
importance for each component. Overall about 1 in 4 high risk people would be
predicted to avoid a major event over 5 years.</p><table-wrap id="pone-0019857-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0019857.t003</object-id><label>Table 3</label><caption><title>Estimated reductions in cardiovascular risk for those remaining on
treatment.</title></caption><alternatives><graphic id="pone-0019857-t003-3" xlink:href="pone.0019857.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Risk factor reduction</td><td colspan="6" align="left" rowspan="1">Proportional risk reduction<xref ref-type="table-fn" rid="nt105">&#x0002a;</xref>
</td><td colspan="2" align="left" rowspan="1">No. needed to treat for 5 yrs to
prevent 1 major event</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CHD</td><td align="left" rowspan="1" colspan="1">Ischaemic stroke</td><td align="left" rowspan="1" colspan="1">Haem-orrhagic stroke<xref ref-type="table-fn" rid="nt106">&#x000b6;</xref>
</td><td align="left" rowspan="1" colspan="1">Major extra-cranial bleed</td><td align="left" rowspan="1" colspan="1">Any major event -moderate risk pop<sup>n</sup>
<xref ref-type="table-fn" rid="nt107">&#x000a7;</xref>
</td><td align="left" rowspan="1" colspan="1">Any major event - high risk pop<sup>n</sup>
<xref ref-type="table-fn" rid="nt107">&#x000a7;</xref>
</td><td align="left" rowspan="1" colspan="1">Moderate risk pop<sup>n</sup>
<xref ref-type="table-fn" rid="nt107">&#x000a7;</xref>
</td><td align="left" rowspan="1" colspan="1">High risk pop<sup>n</sup>
<xref ref-type="table-fn" rid="nt107">&#x000a7;</xref>
</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Blood pressure lowering<sup>16</sup>
</td><td align="left" rowspan="1" colspan="1">10 mmHg lower SBP</td><td align="left" rowspan="1" colspan="1">22&#x00025;</td><td align="left" rowspan="1" colspan="1">41&#x00025;</td><td align="left" rowspan="1" colspan="1">41&#x00025;</td><td align="left" rowspan="1" colspan="1">0&#x00025;</td><td align="left" rowspan="1" colspan="1">26&#x00025;</td><td align="left" rowspan="1" colspan="1">29&#x00025;</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">9</td></tr><tr><td align="left" rowspan="1" colspan="1">Cholesterol lowering<sup>5</sup>
</td><td align="left" rowspan="1" colspan="1">0.8 mmol/L lower LDL</td><td align="left" rowspan="1" colspan="1">35&#x00025;</td><td align="left" rowspan="1" colspan="1">23&#x00025;</td><td align="left" rowspan="1" colspan="1">0&#x00025;</td><td align="left" rowspan="1" colspan="1">0&#x00025;</td><td align="left" rowspan="1" colspan="1">26&#x00025;</td><td align="left" rowspan="1" colspan="1">27&#x00025;</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">9</td></tr><tr><td align="left" rowspan="1" colspan="1">Aspirin<sup>14</sup>
</td><td align="left" rowspan="1" colspan="1">Not applicable</td><td align="left" rowspan="1" colspan="1">20&#x00025;</td><td align="left" rowspan="1" colspan="1">17&#x00025;</td><td align="left" rowspan="1" colspan="1">&#x02212;39&#x00025;</td><td align="left" rowspan="1" colspan="1">&#x02212;54&#x00025;</td><td align="left" rowspan="1" colspan="1">8&#x00025;</td><td align="left" rowspan="1" colspan="1">13&#x00025;</td><td align="left" rowspan="1" colspan="1">125</td><td align="left" rowspan="1" colspan="1">20</td></tr><tr><td align="left" rowspan="1" colspan="1">All three treatments</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">60&#x00025;</td><td align="left" rowspan="1" colspan="1">62&#x00025;</td><td align="left" rowspan="1" colspan="1">18&#x00025;</td><td align="left" rowspan="1" colspan="1">&#x02212;54&#x00025;</td><td align="left" rowspan="1" colspan="1">46&#x00025;</td><td align="left" rowspan="1" colspan="1">53&#x00025;</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">4</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt105"><label/><p>&#x0002a;See <xref ref-type="sec" rid="s2">Methods</xref>. Proportional
effects from systematic reviews<xref rid="pone.0019857-Law2" ref-type="bibr">[5]</xref>, <xref rid="pone.0019857-Law3" ref-type="bibr">[17]</xref>,
<xref rid="pone.0019857-Antithrombotic1" ref-type="bibr">[20]</xref> and given by (1-RR)&#x0002a;100&#x00025;,
where RR is relative risk. Proportional effects of BP and
cholesterol lowering emerge fully after about a year and may vary
slightly by age; those for 60&#x02013;69 year group shown here.</p></fn><fn id="nt106"><label>&#x000b6;</label><p>Proportional effects of blood pressure lowering on haemorrhagic
stroke and ischaemic stroke assumed to be the same as for total
stroke, as most trials have not reported on stroke subtypes. No
effect of statins on haemorrhagic stroke is assumed, reflecting the
overall results from statin trials.<sup>8</sup>
</p></fn><fn id="nt107"><label>&#x000a7;</label><p>Any major event &#x0200a;=&#x0200a; CHD, ischaemic stroke,
haemorrhagic stroke or major extra-cranial bleed. Assumes
pre-treatment annual rates of CHD, ischaemic stroke, haemorrhagic
stroke and major extra-cranial bleed of 1.0&#x00025;, 0.6&#x00025;,
0.1&#x00025;, and 0.2&#x00025; (ie. moderate risk - the average for
this trial population<xref rid="pone.0019857-Anderson1" ref-type="bibr">[13]</xref>, <xref rid="pone.0019857-Antithrombotic1" ref-type="bibr">[20]</xref>, <xref rid="pone.0019857-Longstreth1" ref-type="bibr">[51]</xref>, <xref rid="pone.0019857-Lewis1" ref-type="bibr">[52]</xref>)
and of 4.0&#x00025;, 3.0&#x00025;, 0.3&#x00025; and 0.4&#x00025; (high
risk - expected for people with symptomatic coronary artery
disease<xref rid="pone.0019857-Law6" ref-type="bibr">[29]</xref>, <xref rid="pone.0019857-Fox1" ref-type="bibr">[53]</xref>). These event
rates will vary according to many factors, especially age and
disease history.</p></fn><fn id="nt108"><label/><p>Footnote: Trials indicate this formulation would also affect other
vascular and related outcomes, but in most patient populations these
would have less clinical impact due to lower incidence and/or
severity. Blood pressure lowering would reduce heart failure
incidence (by about a quarter), headache and renal events;<xref rid="pone.0019857-Law3" ref-type="bibr">[17]</xref>,
<xref rid="pone.0019857-Law7" ref-type="bibr">[54]</xref>, <xref rid="pone.0019857-Law8" ref-type="bibr">[55]</xref>, <xref rid="pone.0019857-deGalan1" ref-type="bibr">[56]</xref>aspirin would reduce venous
thromboembolism.[57;, 1994 #1665] An approximately neutral
overall effect on diabetes incidence is expected: ACE-inhibitors
reduce risk<xref rid="pone.0019857-Andraws1" ref-type="bibr">[58]</xref> but this would be offset by small
increases in risk conferred by the low-dose thiazide<xref rid="pone.0019857-Law9" ref-type="bibr">[59]</xref>
and statin.<xref rid="pone.0019857-Sattar1" ref-type="bibr">[60]</xref> Effects on major non-vascular events
would also occur, but similarly the absolute effects would mostly be
small: the thiazide would reduce renal calculus and fracture, and
increase gout;<xref rid="pone.0019857-Law3" ref-type="bibr">[17]</xref>, <xref rid="pone.0019857-Law7" ref-type="bibr">[54]</xref> the statin will
cause rhabdomyolysis (in less than 1 per 10,000 patient years<xref rid="pone.0019857-Law10" ref-type="bibr">[61]</xref>)
and long-term aspirin can be expected to reduce gastrointestinal
cancer by about one-third and all solid cancers by about
one-fifth.<xref rid="pone.0019857-Rothwell1" ref-type="bibr">[62]</xref>
</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s4"><title>Discussion</title><p>These results show that treatment with this polypill achieved sizeable reductions in
SBP and LDL-cholesterol. These risk factor reductions, together with the findings of
systematic reviews of the component medicines, indicate that this treatment can be
expected to more than halve cardiovascular risk. Starting treatment with this
polypill caused side effects sufficient to stop treatment in about 1 in 20 people.
Other less serious side effects occurred in about 1 in 8 people, with most becoming
apparent after just a few weeks of treatment.</p><p>There are several limitations of this study. The relatively short follow-up precluded
assessment of the long-term rates of drop-out. It is well recognized, for example,
that gastric bleeding due to aspirin can occur months or even years after starting
treatment. However, placebo-controlled trials of the separate components of this
polypill show that most long-term drop-out is not related to side effects (i.e.
drop-out rates in the placebo group are much more than half those in the active
group) and that long-term dropout rates are much lower than those observed early
after starting treatment. Nonetheless, the effects on cardiovascular events
estimated here only apply to those staying on treatment long-term. While
characteristic side effects were the only ones evident, the design precluded
definitive attribution of which component caused which side effects. The patient
population represented a relatively narrow group, having raised cardiovascular risk
and no existing indications for any of the medicines. However, history of
symptomatic cardiovascular disease does not modify the extent of risk factor
reductions, which are likely to be broadly generalisable.<xref rid="pone.0019857-Law1" ref-type="bibr">[4]</xref>, <xref rid="pone.0019857-Law2" ref-type="bibr">[5]</xref> Finally, the predicted reductions
in cardiovascular risk are based on reductions in risk factor levels and, while it
appears that blood pressure or LDL-cholesterol reductions account for most or all of
the benefits,<xref rid="pone.0019857-Law3" ref-type="bibr">[17]</xref>,
<xref rid="pone.0019857-Blood1" ref-type="bibr">[18]</xref>, <xref rid="pone.0019857-Cholesterol1" ref-type="bibr">[19]</xref>, <xref rid="pone.0019857-Antithrombotic1" ref-type="bibr">[20]</xref>, <xref rid="pone.0019857-Law4" ref-type="bibr">[21]</xref>, <xref rid="pone.0019857-Boissel1" ref-type="bibr">[31]</xref>, <xref rid="pone.0019857-Staessen1" ref-type="bibr">[32]</xref> these are
nonetheless indirect estimates.</p><p>Two previous trials have assessed the effects of polypill treatment compared to
control on risk factor reductions, tolerability and estimated cardiovascular risk,
and their results are compared with the current study and Wald and Law's
original predictions in <xref ref-type="table" rid="pone-0019857-t004">Table
4</xref>. The Indian Polycap Study (TIPS) randomized 2,053 individuals without
cardiovascular disease, aged 45&#x02013;80 years and with one or more risk factors, to
12 weeks treatment with the Polycap (hydrochlorothiazide 12&#x000b7;5 mg, atenolol 50
mg, ramipril 5 mg, simvastatin 20 mg and aspirin 100 mg), or to one of eight other
groups: aspirin alone, simvastatin alone, hydrochlorothiazide alone, three
combinations of the two blood pressure lowering drugs, three blood pressure lowering
drugs alone, or three blood pressure lowering drugs plus aspirin.<sup><xref rid="pone.0019857-The2" ref-type="bibr">[23]</xref></sup> This
design allowed demonstration that the risk factor reductions from each treatment
modality were essentially the same in the presence and absence of other
treatments.<sup><xref rid="pone.0019857-The2" ref-type="bibr">[23]</xref></sup> Malekzadeh et al conducted a double-blind
randomised placebo controlled trial in residents of Golestan, Iran.<xref rid="pone.0019857-Malekzadeh1" ref-type="bibr">[33]</xref> Following
an 8-week placebo run-in period, 475 participants, aged 50 to 79 years, without
cardiovascular disease, hypertension or hyperlipidaemia were randomised to
fixed-dose combination therapy (aspirin 81 mg, enalapril 2.5 mg, atorvastatin 20 mg
and hydrochlorothiazide 12.5 mg) or placebo for a period of 12 months. Both trials
had relatively high non-attendance at final follow-up: 16&#x00025; in TIPS and
27&#x00025; in the Malekzadeh et al trial (22&#x00025; in the control group and
33&#x00025; in the polypill group, p&#x0200a;=&#x0200a;0.02 for difference),
compared to 1&#x00025; in the current trial. Therefore TIPS and in particular the
Malekzadeh et al trial were more prone to bias, especially when assessing side
effects since these are often associated with loss to follow-up.</p><table-wrap id="pone-0019857-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0019857.t004</object-id><label>Table 4</label><caption><title>Comparison with previous polypill studies.</title></caption><alternatives><graphic id="pone-0019857-t004-4" xlink:href="pone.0019857.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Formulation</td><td colspan="2" align="left" rowspan="1">Blood pressure (mmHg)</td><td colspan="2" align="left" rowspan="1">LDL-cholesterol (mmol/l)</td><td colspan="2" align="left" rowspan="1">Placebo-corrected absolute excess of side
effects<xref ref-type="table-fn" rid="nt110">&#x0002a;&#x0002a;</xref>
</td><td colspan="2" align="left" rowspan="1">Estimated proportional risk reduction</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Baseline level</td><td align="left" rowspan="1" colspan="1">Reduction</td><td align="left" rowspan="1" colspan="1">Baseline level</td><td align="left" rowspan="1" colspan="1">Reduction</td><td align="left" rowspan="1" colspan="1">Sufficient to stop treatment in short term</td><td align="left" rowspan="1" colspan="1">Causing any symptoms</td><td align="left" rowspan="1" colspan="1">CHD</td><td align="left" rowspan="1" colspan="1">Stroke</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Wald and Law<xref ref-type="table-fn" rid="nt109">&#x0002a;</xref>
<xref rid="pone.0019857-Law1" ref-type="bibr">[4]</xref>, <xref rid="pone.0019857-Law2" ref-type="bibr">[5]</xref>, <xref rid="pone.0019857-Wald1" ref-type="bibr">[6]</xref>
</td><td align="left" rowspan="1" colspan="1">Statin (eg. simvastatin 40 mg), three &#x000bd; strength
blood pressure drugs, aspirin 75 mg</td><td align="left" rowspan="1" colspan="1">150/90</td><td align="left" rowspan="1" colspan="1">20/11</td><td align="left" rowspan="1" colspan="1">4.8</td><td align="left" rowspan="1" colspan="1">1.8</td><td align="left" rowspan="1" colspan="1">2&#x00025;</td><td align="left" rowspan="1" colspan="1">8&#x02013;15&#x00025;</td><td align="left" rowspan="1" colspan="1">86&#x00025;</td><td align="left" rowspan="1" colspan="1">74&#x00025;</td></tr><tr><td align="left" rowspan="1" colspan="1">TIPS<xref rid="pone.0019857-The2" ref-type="bibr">[23]</xref>
</td><td align="left" rowspan="1" colspan="1">Simvastatin 20 mg, hydrochlorothiazide 12&#x000b7;5 mg,
atenolol 50 mg, ramipril 5 mg, aspirin 100 mg</td><td align="left" rowspan="1" colspan="1">134/85</td><td align="left" rowspan="1" colspan="1">7/6</td><td align="left" rowspan="1" colspan="1">3.0</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">62&#x00025;</td><td align="left" rowspan="1" colspan="1">48&#x00025;</td></tr><tr><td align="left" rowspan="1" colspan="1">Malekzadeh et al <xref rid="pone.0019857-Malekzadeh1" ref-type="bibr">[33]</xref>
</td><td align="left" rowspan="1" colspan="1">Atorvastatin 20 mg, enalapril 2.5 mg,
hydrochlorothiazide 12.5 mg, aspirin 81 mg</td><td align="left" rowspan="1" colspan="1">128/79</td><td align="left" rowspan="1" colspan="1">5/2</td><td align="left" rowspan="1" colspan="1">3.0</td><td align="left" rowspan="1" colspan="1">0.5</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">34&#x00025;</td><td align="left" rowspan="1" colspan="1">21&#x00025;</td></tr><tr><td align="left" rowspan="1" colspan="1">Current trial</td><td align="left" rowspan="1" colspan="1">Simvastatin 20 mg, hydrochlorothiazide 12&#x000b7;5 mg,
lisinopril 10 mg, aspirin 75 mg</td><td align="left" rowspan="1" colspan="1">134/81</td><td align="left" rowspan="1" colspan="1">10/5</td><td align="left" rowspan="1" colspan="1">3.7</td><td align="left" rowspan="1" colspan="1">0.8</td><td align="left" rowspan="1" colspan="1">5&#x00025;</td><td align="left" rowspan="1" colspan="1">16&#x00025;</td><td align="left" rowspan="1" colspan="1">60&#x00025;</td><td align="left" rowspan="1" colspan="1">56&#x00025;</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt109"><label/><p>&#x0002a;Estimated rather than observed risk factor reductions and side
effects. Predictions for formulation without folic acid.</p></fn><fn id="nt110"><label/><p>&#x0002a;&#x0002a;Not estimable for TIPS due to lack of placebo control and side
effects not reported reliably in Malekzadeh et al trial (see <xref ref-type="sec" rid="s4">Discussion</xref>). Side effects
&#x02018;causing any symptoms&#x02019; refers to those observed in 12 weeks
treatment for current trial and predictions for both short and long term
treatment by Wald and Law. This excess was estimated at 8&#x00025; for a
formulation containing a thiazide, angiotensin II receptor blocker and
calcium channel blocker and 15&#x00025; for a formulation containing a
thiazide, beta-blocker, and ACE inhibitor.</p></fn></table-wrap-foot></table-wrap><p>The risk factor reductions in TIPS were comparable in size to those observed in the
current trial, even though the Polycap contained an additional blood pressure
lowering agent. At the end of 12 weeks, 66/412 (16&#x00025;) people in the Polycap
group had stopped taking study treatment compared to 34/189 (18&#x00025;) in the
current trial. TIPS could not estimate total excess (ie. placebo-corrected) side
effects, since each comparison group contained at least one active component.
However it did report no clear difference in side effect rates between the different
active groups. The risk factor reductions in the Malekzadeh trial were notably lower
than both TIPS and the current trial, but this may well be due to low baseline
levels (which were differential between the groups for blood pressure, p&#x0003c;0.0001),
loss to follow-up and non-adherence. The reported rates of side effects were also
very low, with only 40/475 (8&#x00025;) participants reporting reluctance to take
study treatment and only 2/475 (0.4&#x00025;) reporting adverse drug reactions. This
is likely to be in large part attributable to the combined impact of loss to
follow-up, under-reporting and non-adherence.</p><p>One further active-controlled trial has recently been completed, in which 216
individuals from Sri Lanka who were aged over 50 years old if female and over 40
years if male, and who had an estimated 10-year total CVD risk score &#x0003e;20&#x00025;,
based on WHO CVD risk prediction charts, were randomized to a polypill (containing
75 mg aspirin, 20 mg simvastatin, 10 mg lisinopril and 12.5 mg hydrochlorothiazide)
or to standard practice.<xref rid="pone.0019857-Soliman1" ref-type="bibr">[34]</xref> The results suggested similar reduction in risk factors
and predicted cardiovascular risk in both groups.</p><p>This is the first trial to empirically test Wald and Law's predictions of side
effects attributable to a polypill: <xref ref-type="table" rid="pone-0019857-t004">Table 4</xref> shows that the observed excess of side effects is considerably
greater than that predicted. The risk factor reductions seen in the current trial
are also about half the size predicted by Wald and Law,<xref rid="pone.0019857-Wald1" ref-type="bibr">[6]</xref> mostly because those estimates
were based on higher baseline risk factor levels, use of a more potent statin and an
extra blood pressure lowering agent. Interestingly however the estimated reductions
in CHD and stroke from this polypill are only about 25&#x02013;30&#x00025; smaller than
those of Wald and Law. This is because of the diminishing marginal returns from
additional reductions in single risk factors, and the multiplicative benefits of
adding different treatment modalities ie. less risk reduction from one modality
leaves &#x02018;more to slice off&#x02019; for the next modality.</p><p>What are the implications of these findings for research and clinical practice? Among
patients at low-to-moderate global cardiovascular risk, further work is required on
polypill formulations and target patient populations. This trial suggests that the
short-term tolerability of a polypill is not as good as previous predictions or
trials have suggested, although still nonetheless causing no symptoms in 5 out of 6
people treated. Most side effects, including virtually all major ones, would be due
to aspirin, and the inclusion of aspirin in combination treatment provides modest
net benefits,<xref rid="pone.0019857-Antithrombotic1" ref-type="bibr">[20]</xref> although recent data showing that aspirin reduces the
incidence of cancer will change this risk-balance equation back again. Nonetheless,
even among patients at moderately elevated risk, such as the average in this trial
(which is considerably higher than the risk faced by individuals with, for example,
uncomplicated hypertension, dyslipidaemia or diabetes) the absolute benefits of
aspirin would be small. For such individuals whose risk has first been reduced by
blood pressure and cholesterol lowering, aspirin would only avoid a major event in
every thousand or more patients per year. Polypills based on blood pressure and
cholesterol lowering agents are therefore required, along with research on their
benefits and risks compared to usual care. An area of controversy will be whether
such trials should assess hard cardiovascular endpoints (taking many years to
complete) or just measure side effects and BP and LDL reduction, given the
conclusive evidence of the event reduction from individual treatments, the lack of
interaction between the treatments, and the finding that most or all of the benefits
are due to the extent of BP or LDL reduction. <xref rid="pone.0019857-Law3" ref-type="bibr">[17]</xref>, <xref rid="pone.0019857-Cholesterol1" ref-type="bibr">[19]</xref>, <xref rid="pone.0019857-Antithrombotic1" ref-type="bibr">[20]</xref>, <xref rid="pone.0019857-Law5" ref-type="bibr">[22]</xref> One further issue is that although
efficacy of blood pressure and cholesterol lowering has been clearly established
well below historical &#x02018;hypertension&#x02019; and &#x02018;dyslipidaemia&#x02019;
thresholds,<xref rid="pone.0019857-Law4" ref-type="bibr">[21]</xref>,
<xref rid="pone.0019857-Jackson3" ref-type="bibr">[35]</xref>, <xref rid="pone.0019857-Thompson1" ref-type="bibr">[36]</xref> indications
currently approved by regulatory authorities and much clinical practice is
restricted to those with &#x02018;hypertension&#x02019; or &#x02018;dyslipidaemia&#x02019;
(regardless of the level of cardiovascular risk).</p><p>Among patients with a history of occlusive vascular disease, further evidence on
efficacy for individual medication classes is not required, since this has been
established with clinical trials involving many tens of thousands of patient over
half a century. All major cross-disciplinary guidelines<xref rid="pone.0019857-British1" ref-type="bibr">[9]</xref>, <xref rid="pone.0019857-The2" ref-type="bibr">[23]</xref>, <xref rid="pone.0019857-DeBacker1" ref-type="bibr">[37]</xref> recommend some form of blood
pressure lowering, cholesterol lowering and antiplatelet therapy in patients with
vascular disease. Research is therefore only required on the comparative roles of
polypill-based treatment compared to usual care in delivering these therapies
long-term. People with previous symptomatic vascular disease are relatively easily
identified, more motivated to take treatment and account for almost half of all
major cardiovascular events. Among this group the benefits of this combination
therapy substantially outweigh the side effects, and one could reasonably expect
similar-sized benefits in asymptomatic patients at equivalently high risk, who
comprise about 5&#x00025; of the adult population.<xref rid="pone.0019857-Wells1" ref-type="bibr">[38]</xref> Yet the vast majority of
highest-risk people globally do not receive such treatment long-term. In
economically developed countries most are now prescribed recommended medicines after
an acute event, but many do not continue: only one- to two-thirds of people with a
history of vascular disease take antiplatelet, blood pressure lowering and statin
therapy long-term.<xref rid="pone.0019857-Kotseva1" ref-type="bibr">[39]</xref>, <xref rid="pone.0019857-Webster1" ref-type="bibr">[40]</xref>, <xref rid="pone.0019857-Kumar1" ref-type="bibr">[41]</xref>, <xref rid="pone.0019857-World3" ref-type="bibr">[42]</xref> In economically developing countries, where 80&#x00025; of
the global burden of cardiovascular disease occurs,<xref rid="pone.0019857-Beaglehole1" ref-type="bibr">[43]</xref> very few receive these
medicines in the short or long-term.<xref rid="pone.0019857-Mendis1" ref-type="bibr">[44]</xref>, <xref rid="pone.0019857-Sharma1" ref-type="bibr">[45]</xref> With current approaches, these treatment gaps are closing
very slowly.<xref rid="pone.0019857-Selak1" ref-type="bibr">[46]</xref>
Increasing access to treatment is a potentially highly cost-effective strategy<xref rid="pone.0019857-Murray1" ref-type="bibr">[47]</xref>, <xref rid="pone.0019857-Gaziano1" ref-type="bibr">[48]</xref>, <xref rid="pone.0019857-Goldberg1" ref-type="bibr">[49]</xref> and alone
could achieve most of WHO's goals for reducing non-communicable disease.<xref rid="pone.0019857-Lim1" ref-type="bibr">[50]</xref>
</p></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0019857.s001"><label>Protocol S1</label><caption><p>Trial Protocol</p><p>(DOC)</p></caption><media xlink:href="pone.0019857.s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0019857.s002"><label>Checklist S1</label><caption><p>CONSORT Checklist</p><p>(PDF)</p></caption><media xlink:href="pone.0019857.s002.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>
<bold>The Program to Improve Life and Longevity (PILL) Collaborative Group</bold>
</p><p>
<bold>Steering and Writing Committee</bold>
</p><p>Anthony Rodgers (Chair), The George Institute for Global Health, Sydney, NSW,
Australia</p><p>Anushka Patel, The George Institute for Global Health, Sydney, NSW, Australia</p><p>Otavio Berwanger, Hospital do Cora&#x000e7;&#x000e3;o, Sao Paolo, Brazil</p><p>Michiel Bots, Julius Center for Health Sciences and Primary Care, Utrecht, The
Netherlands</p><p>Richard Grimm, Berman Center for Outcomes and Clinical Research, Minneapolis,
Minnesota, USA</p><p>Diederick E. Grobbee, Julius Center for Health Sciences and Primary Care, Utrecht,
The Netherlands</p><p>Rod Jackson, School of Population Health, The University of Auckland, Auckland, New
Zealand</p><p>Bruce Neal, The George Institute for Global Health, Sydney, NSW, Australia</p><p>Jim Neaton, Division of Biostatistics, University of Minnesota, Minneapolis,
Minnesota, USA</p><p>Neil Poulter, International Centre for Circulatory Health, London, United Kingdom</p><p>Natasha Rafter, formerly Clinical Trials Research Unit, The University of Auckland,
Auckland, New Zealand</p><p>P Krishnam Raju, Care Hospitals, Hyderabad, Andhra Pradesh, India</p><p>Srinath Reddy, The Public Health Foundation of India, New Delhi, India</p><p>Simon Thom, International Centre for Circulatory Health, Imperial College, London,
United Kingdom</p><p>Stephen Vander Hoorn, formerly Clinical Trials Research Unit, The University of
Auckland, Auckland, New Zealand</p><p>Assisted by Ruth Webster, The George Institute for Global Health, Sydney, NSW,
Australia.</p><p>
<bold>International Co-ordinating Centre &#x02013; The Clinical Trials Research Unit,
Auckland</bold>
</p><p>Project Manager: Angela Wadham</p><p>Research Fellow: Vanessa Selak, Natasha Rafter</p><p>Statistican: Steve Vander Hoorn, Joy Jiang</p><p>Data Management: Rina Prasad, John Faatui, Tamsin Scott, Amanda Milne</p><p>IT: Barry Gray, Colleen Ng, Johan Strydom</p><p>
<bold>Australia centre - The George Institute for Global Health, Sydney</bold>
</p><p>Principal Investigator: Anushka Patel</p><p>Project Manager: Bindu Patel, Paula Zeman</p><p>Monitor: Oscar-Hazel Donaldson</p><p>Investigators: Joseph Canalese, Patrick Groenstein, Kumara Mendis, David Sullivan</p><p>Local Co-ordinators: Kerry Kearns, Nicole Li, Toni Monico, Evelyn Nangle, Chloe
Runeckles</p><p>
<bold>Brazil centre - Hospital do Cora&#x000e7;&#x000e3;o, Sao Paolo</bold>
</p><p>Principal Investigator: Otavio Berwanger</p><p>Project Manager: Ligia Nasi Laranjeira, Anna Maria Buchler</p><p>Monitor: Andrea Di Vanna</p><p>Investigators: Alexandre Biasi, Helio Penna Guimaraes, Nora Falconi</p><p>Local Co-ordinators: Cyntia Da Silva, Elaine Bastos De Menezes</p><p>
<bold>India centre The George Institute for Global Health, Hyderabad</bold>
</p><p>Principal Investigator: Anushka Patel</p><p>Project Manager: Bindu Patel</p><p>Monitor: M.Abdul Salam</p><p>Investigators: Ashok Kumar Dash, Kalyana Chakravarthy, Gundala Anil Krishna,
Panchangam Sampath Kumar, Ravi Jayam</p><p>Local Co-ordinators: Mohammed Abdul Azeem Imran, Vemulakonda Sushma, Hari Obulesu,
Syed Fayaz, Kasparam Mahesh</p><p>
<bold>New Zealand centre - The Clinical Trials Research Unit, Auckland</bold>
</p><p>Principal Investigator: Anthony Rodgers</p><p>Project Manager and Monitor: Angela Wadham</p><p>Investigators: Fiona McLean, James Smith, Christine Forster, Malcolm Lowe, Harley
Aish, John Cameron</p><p>Local Co-ordinator: Denise Miller</p><p>
<bold>The Netherlands centre - Julius Center for Health Sciences and Primary Care,
Utrecht</bold>
</p><p>Principal Investigators: Diederick E Grobbee and Michiel Bots</p><p>Project Manager: Lizeth Vendrig</p><p>Monitor: Gonnie Vierstra, Ischa Vissers, Jacobien Vermande, Karin Groot</p><p>Investigators: Deborah Font-Julia, Hans Zuidema, Marcel VanDyk, Ron Peters, Sara
Rafi, Suthesh Sivapalaratnam</p><p>Local Co-ordinators: Janneke van den Brink, Liselotte Kok, Lydeke Zwart, Trees
Groenveld, Hanneke Basart</p><p>
<bold>UK centre - International Centre for Circulatory Health, London,</bold>
</p><p>Principal Investigators: Simon Thom and Neil Poulter</p><p>Project Manager and Monitor: Thiagarajah Sasikaran</p><p>Investigators: Filomena Paciello and Judith Mackay</p><p>Local Co-ordinators: Hannah Lanzon-Miller, Jill Bunker, Candida Coghlan, Rachel
Chapman, Rebecca Webb, Wendy Callister</p><p>
<bold>USA centre - Berman Center for Outcomes and Clinical Research,
Minneapolis</bold>
</p><p>Principal Investigator: Richard Grimm</p><p>Project Manager: Rachel Moor</p><p>Monitor: Margaret Dimond</p><p>Investigators: Mobin Malik</p><p>Local Co-ordinators: Alexa Camarena-Michel</p><p>
<bold>Dr Reddy</bold>'<bold>s liaison</bold>
</p><p>Raghu Cidambi, Asit Datta, Haranath Robby, Arvind Ananthakrishnan, Prakash Shenthar
Mahalinga, Neetta Mohit, Rajesh Dubey, Rekha Sinha</p><p>All members would like to acknowledge and thank the trial participants</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>The trial was funded by The Wellcome Trust, the Health Research Council of New
Zealand, the National Heart Foundation of New Zealand, the National Health and
Medical Research Council of Australia, The Brazilian Ministry of Health (Projeto
Hospitais de Excelencia) and the British Heart Foundation. The polypill and
matching placebo were provided free of charge by Dr. Reddy's Laboratories,
Hyderabad, India. None of these parties had any role in study design, data
collection, data analysis, data interpretation, or writing of the report. The
corresponding author had full access to all data in the study. The Steering
Committee had final responsibility for the decision to submit for
publication.</p></fn></fn-group><ref-list><title>References</title><ref id="pone.0019857-World1"><label>1</label><element-citation publication-type="book">
<collab>World Health Organization</collab>
<year>2002</year>
<article-title>Secondary prevention of non-communicable disease in low and
middle income countries through community-based and health service
interventions.</article-title>
<publisher-name>World Health Organization - Wellcome Trust meeting report 1 - 3
August 2001, Geneva</publisher-name>
</element-citation></ref><ref id="pone.0019857-World2"><label>2</label><element-citation publication-type="book">
<collab>World Health Organization</collab>
<year>2002</year>
<article-title>The World Health Report 2002.</article-title>
<person-group person-group-type="editor"><collab>Reducing risks,promoting healthy life WHO</collab></person-group>
<publisher-loc>Geneva</publisher-loc>
<publisher-name>WHO</publisher-name>
</element-citation></ref><ref id="pone.0019857-Yusuf1"><label>3</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yusuf</surname><given-names>S</given-names></name></person-group>
<year>2002</year>
<article-title>Two decades of progress in preventing vascular
disease.</article-title>
<source>Lancet</source>
<volume>360</volume>
<fpage>2</fpage>
<lpage>3</lpage>
<pub-id pub-id-type="pmid">12114031</pub-id></element-citation></ref><ref id="pone.0019857-Law1"><label>4</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Law</surname><given-names>MR</given-names></name><name><surname>Wald</surname><given-names>NJ</given-names></name><name><surname>Morris</surname><given-names>JK</given-names></name><name><surname>Jordan</surname><given-names>RE</given-names></name></person-group>
<year>2003</year>
<article-title>Value of low dose combination treatment with blood pressure
lowering drugs: analysis of 354 randomised trials.</article-title>
<source>British Medical Journal</source>
<volume>326</volume>
<fpage>1427</fpage>
<lpage>1431</lpage>
<pub-id pub-id-type="pmid">12829555</pub-id></element-citation></ref><ref id="pone.0019857-Law2"><label>5</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Law</surname><given-names>MR</given-names></name><name><surname>Wald</surname><given-names>NJ</given-names></name><name><surname>Rudnicka</surname><given-names>AR</given-names></name></person-group>
<year>2003</year>
<article-title>Quantifying effect of statins on low density lipoprotein
cholesterol, ischaemic heart disease, and stroke: systematic review and
meta-analysis.</article-title>
<source>British Medical Journal</source>
<volume>326</volume>
<fpage>1423</fpage>
<lpage>1430</lpage>
<pub-id pub-id-type="pmid">12829554</pub-id></element-citation></ref><ref id="pone.0019857-Wald1"><label>6</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wald</surname><given-names>NJ</given-names></name><name><surname>Law</surname><given-names>MR</given-names></name></person-group>
<year>2003</year>
<article-title>A strategy to reduce cardiovascular disease by more than
80&#x00025;.</article-title>
<source>British Medical Journal</source>
<volume>326</volume>
</element-citation></ref><ref id="pone.0019857-Wald2"><label>7</label><element-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Wald</surname><given-names>NJ</given-names></name><name><surname>Law</surname><given-names>MR</given-names></name></person-group>
<year>2001</year>
<article-title>Formulation For The Prevention Of Cardiovascular
Disease.</article-title>
<source>WO</source>
</element-citation></ref><ref id="pone.0019857-Fourth1"><label>8</label><element-citation publication-type="journal">
<collab>Fourth joint task force of the European Joint Society of Cardiology and
Other Societies on cardiovascular disease prevention in clinical
practice</collab>
<year>2007</year>
<article-title>European guidelines on cardiovascular disease prevention in
clinical practice: executive summary.</article-title>
<source>European Heart Journal</source>
<volume>28</volume>
<fpage>2375</fpage>
<lpage>2414</lpage>
<pub-id pub-id-type="pmid">17726041</pub-id></element-citation></ref><ref id="pone.0019857-British1"><label>9</label><element-citation publication-type="journal">
<collab>British Cardiac SocietyBritish Hypertension SocietyDiabetes UKHeart
UKPrimary Care Cardiovascular Society</collab>
<year>2005</year>
<article-title>JSB2: Joint British Societies' guidelines on prevention of
cardiovascular disease in clinical practice.</article-title>
<source>Heart</source>
<volume>91</volume>
<fpage>1</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="pmid">15604317</pub-id></element-citation></ref><ref id="pone.0019857-The1"><label>10</label><element-citation publication-type="journal">
<collab>The National Vascular Disease Prevention Alliance (Diabetes Australia
KHA National Heart Foundation of Australia, and National Stroke Foundation
of Australia)</collab>
<year>2004</year>
<article-title>Consensus statement for the prevention of vascular
disease.</article-title>
<source>Australian Family Physician</source>
<volume>33</volume>
</element-citation></ref><ref id="pone.0019857-New1"><label>11</label><element-citation publication-type="book">
<collab>New Zealand Guidelines Group</collab>
<year>2003</year>
<article-title>Evidence-based best practice guideline.</article-title>
<source>The assessment and management of cardiovascular risk</source>
<publisher-name>New Zealand Guidelines Group</publisher-name>
</element-citation></ref><ref id="pone.0019857-European1"><label>12</label><element-citation publication-type="other">
<collab>European Agency for the Evaluation of Medicinal Products (EMA)</collab>
<year>2008</year>
<source>Guideline on the Evaluation of Medicinal Products for Cardiovascular
Disease Prevention</source>
</element-citation></ref><ref id="pone.0019857-Anderson1"><label>13</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Anderson</surname><given-names>K</given-names></name><name><surname>Wilson</surname><given-names>P</given-names></name><name><surname>Odell</surname><given-names>P</given-names></name><name><surname>Kannel</surname><given-names>W</given-names></name></person-group>
<year>1991</year>
<article-title>An updated coronary risk profile. A statement for health
professionals.</article-title>
<source>Circulation</source>
<volume>83</volume>
<fpage>356</fpage>
<lpage>362</lpage>
<pub-id pub-id-type="pmid">1984895</pub-id></element-citation></ref><ref id="pone.0019857-Jackson1"><label>14</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jackson</surname><given-names>R</given-names></name><name><surname>Barham</surname><given-names>P</given-names></name><name><surname>Bills</surname><given-names>J</given-names></name><name><surname>Birch</surname><given-names>T</given-names></name><name><surname>McLennan</surname><given-names>L</given-names></name><etal/></person-group>
<year>1993</year>
<article-title>Management of raised blood pressure in New Zealand: a discussion
document.</article-title>
<source>British Medical Journal</source>
<volume>307</volume>
<fpage>107</fpage>
<lpage>110</lpage>
<pub-id pub-id-type="pmid">8343706</pub-id></element-citation></ref><ref id="pone.0019857-Riddell1"><label>15</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Riddell</surname><given-names>T</given-names></name><name><surname>Wells</surname><given-names>S</given-names></name><name><surname>Jackson</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>AW</given-names></name><name><surname>Crengle</surname><given-names>S</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>Performance of Framingham cardiovascular risk scores by ethnic
groups in New Zealand: PREDICT CVD-10.</article-title>
<source>New Zealand Medical Journal</source>
<volume>123</volume>
<fpage>50</fpage>
<lpage>61</lpage>
</element-citation></ref><ref id="pone.0019857-Using1"><label>16</label><element-citation publication-type="book">
<year>2007</year>
<article-title>Using Framingham for primary prevention cardiovascular risk
assessment.</article-title>
<publisher-name>Therapeutics Letter</publisher-name>
<comment>63/ MAR - APR</comment>
</element-citation></ref><ref id="pone.0019857-Law3"><label>17</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Law</surname><given-names>MR</given-names></name><name><surname>Morris</surname><given-names>JK</given-names></name><name><surname>Wald</surname><given-names>NJ</given-names></name></person-group>
<year>2009</year>
<article-title>Use of blood pressure lowering drugs in the prevention of
cardiovascular disease: meta-analysis of 147 randomised trials in the
context of expectations from prospective epidemiological
studies.</article-title>
<source>British Medical Journal</source>
<volume>338</volume>
</element-citation></ref><ref id="pone.0019857-Blood1"><label>18</label><element-citation publication-type="journal">
<collab>Blood Pressure Lowering Treatment Trialists C</collab>
<year>2008</year>
<article-title>Effects of different regimens to lower blood pressure on major
cardiovascular events in older and younger adults: meta-analysis of
randomised trials.</article-title>
<source>British Medical Journal</source>
<volume>336</volume>
<fpage>1121</fpage>
<lpage>1123</lpage>
<pub-id pub-id-type="pmid">18480116</pub-id></element-citation></ref><ref id="pone.0019857-Cholesterol1"><label>19</label><element-citation publication-type="journal">
<collab>Cholesterol Treatment Trialists' (CTT) Collaboration</collab>
<year>2005</year>
<article-title>Efficacy and safety of cholesterol-lowering treatment:
prospective meta-analysis of data from 90 056 participants in 14 randomised
trials of statins.</article-title>
<source>Lancet</source>
<volume>366</volume>
<fpage>1267</fpage>
<lpage>1278</lpage>
<pub-id pub-id-type="pmid">16214597</pub-id></element-citation></ref><ref id="pone.0019857-Antithrombotic1"><label>20</label><element-citation publication-type="journal">
<collab>Antithrombotic Trialists Collaboration</collab>
<year>2009</year>
<article-title>Aspirin in the primary and secondary prevention of vascular
disease: collaborative meta-analysis of individual participant data from
randomised trials.</article-title>
<source>The Lancet</source>
<volume>373</volume>
<fpage>1849</fpage>
<lpage>1860</lpage>
</element-citation></ref><ref id="pone.0019857-Law4"><label>21</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Law</surname><given-names>M</given-names></name><name><surname>Wald</surname><given-names>N</given-names></name></person-group>
<year>2002</year>
<article-title>Risk factor thresholds: their existence under
scrutiny.</article-title>
<source>British Medical Journal</source>
<volume>324</volume>
<fpage>1570</fpage>
<lpage>1576</lpage>
<pub-id pub-id-type="pmid">12089098</pub-id></element-citation></ref><ref id="pone.0019857-Law5"><label>22</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Law</surname><given-names>MR</given-names></name><name><surname>Wald</surname><given-names>NJ</given-names></name><name><surname>Morris</surname><given-names>JK</given-names></name></person-group>
<year>2003</year>
<article-title>Lowering blood pressure to prevent myocardial infarction and
stroke: a new preventive strategy.</article-title>
<source>British Medical Journal</source>
<volume>7</volume>
</element-citation></ref><ref id="pone.0019857-The2"><label>23</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yusuf</surname><given-names>S</given-names></name><name><surname>Pais</surname><given-names>P</given-names></name><name><surname>Afzal</surname><given-names>R</given-names></name><name><surname>Xavier</surname><given-names>D</given-names></name><etal/></person-group>
<collab>The Indian Polycap Study</collab>
<year>2009</year>
<article-title>Effects of a polypill (Polycap) on risk factors in middle-aged
individuals without cardiovascular disease (TIPS): a phase II, double-blind,
randomised trial.</article-title>
<source>Lancet</source>
<volume>373</volume>
<fpage>1341</fpage>
<lpage>1351</lpage>
<pub-id pub-id-type="pmid">19339045</pub-id></element-citation></ref><ref id="pone.0019857-Asia1"><label>24</label><element-citation publication-type="journal">
<collab>Asia Pacific Cohort Studies C</collab>
<year>2005</year>
<article-title>Joint effects of systolic blood pressure and serum cholesterol on
cardiovascular disease in the Asia Pacific region.</article-title>
<source>Circulation</source>
<volume>112</volume>
<fpage>3384</fpage>
<lpage>3390</lpage>
<pub-id pub-id-type="pmid">16301345</pub-id></element-citation></ref><ref id="pone.0019857-ProspectiveStudies1"><label>25</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Prospective Studies</surname><given-names>C</given-names></name><name><surname>Lewington</surname><given-names>S</given-names></name><name><surname>Whitlock</surname><given-names>G</given-names></name><name><surname>Clarke</surname><given-names>R</given-names></name><name><surname>Sherliker</surname><given-names>P</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Blood cholesterol and vascular mortality by age, sex, and blood
pressure: a meta-analysis of individual data from 61 prospective studies
with 55,000 vascular deaths.</article-title>
<source>Lancet</source>
<volume>370</volume>
<fpage>1829</fpage>
<lpage>1839</lpage>
<pub-id pub-id-type="pmid">18061058</pub-id></element-citation></ref><ref id="pone.0019857-Glasziou1"><label>26</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Glasziou</surname><given-names>PP</given-names></name><name><surname>Irwig</surname><given-names>LM</given-names></name></person-group>
<year>1995</year>
<article-title>An evidence based approach to individualising
treatment.</article-title>
<source>British Medical Journal</source>
<volume>311</volume>
<fpage>1356</fpage>
<lpage>1359</lpage>
<pub-id pub-id-type="pmid">7496291</pub-id></element-citation></ref><ref id="pone.0019857-Jackson2"><label>27</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jackson</surname><given-names>R</given-names></name><name><surname>Lawes</surname><given-names>CMM</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name><name><surname>Milne</surname><given-names>RJ</given-names></name><name><surname>Rodgers</surname><given-names>A</given-names></name></person-group>
<year>2005</year>
<article-title>Treatment with drugs to lower blood pressure and blood
cholesterol based on an individual's absolute cardiovascular
risk.</article-title>
<source>The Lancet</source>
<volume>365</volume>
<fpage>434</fpage>
<lpage>441</lpage>
</element-citation></ref><ref id="pone.0019857-Chobanian1"><label>28</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chobanian</surname><given-names>AV</given-names></name><name><surname>Bakris</surname><given-names>GL</given-names></name><name><surname>Black</surname><given-names>HR</given-names></name><name><surname>Cushman</surname><given-names>WC</given-names></name><name><surname>Green</surname><given-names>LA</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>The Seventh Report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure.</article-title>
<source>Journal of the American Medical Association</source>
<volume>289</volume>
<fpage>2560</fpage>
<lpage>2572</lpage>
<comment>The JNC 7 Report</comment>
<pub-id pub-id-type="pmid">12748199</pub-id></element-citation></ref><ref id="pone.0019857-Law6"><label>29</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Law</surname><given-names>MR</given-names></name><name><surname>Watt</surname><given-names>HC</given-names></name><name><surname>Wald</surname><given-names>NJ</given-names></name></person-group>
<year>2002</year>
<article-title>The underlying risk of death after myocardial infarction in the
absence of treatment.</article-title>
<source>Arch Intern Med</source>
<volume>162</volume>
<fpage>2405</fpage>
<lpage>2410</lpage>
<pub-id pub-id-type="pmid">12437397</pub-id></element-citation></ref><ref id="pone.0019857-Steg1"><label>30</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Steg</surname><given-names>PG</given-names></name><name><surname>Goldberg</surname><given-names>RJ</given-names></name><name><surname>Gore</surname><given-names>JM</given-names></name><name><surname>Fox</surname><given-names>KAA</given-names></name><name><surname>Eagle</surname><given-names>KA</given-names></name><etal/></person-group>
<year>2002</year>
<article-title>Baseline characteristics, management practices, and in-hospital
outcomes of patients hospitalized with acute coronary syndromes in the
Global Registry of Acute Coronary Events (GRACE).</article-title>
<source>American Journal of Cardiology</source>
<volume>90</volume>
<fpage>358</fpage>
<lpage>363</lpage>
<pub-id pub-id-type="pmid">12161222</pub-id></element-citation></ref><ref id="pone.0019857-Boissel1"><label>31</label><element-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Boissel</surname><given-names>JP</given-names></name><name><surname>Gueyffier</surname><given-names>F</given-names></name><name><surname>Boutitie</surname><given-names>F</given-names></name><name><surname>Pocock</surname><given-names>S</given-names></name><name><surname>Fagard</surname><given-names>R.</given-names></name></person-group>
<article-title>Apparent effect on blood pressure is only partly responsible for
the risk reduction due to antihypertensive treatments</article-title>
</element-citation></ref><ref id="pone.0019857-Staessen1"><label>32</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Staessen</surname><given-names>JA</given-names></name><name><surname>Wang</surname><given-names>JG</given-names></name><name><surname>Thijs</surname><given-names>L</given-names></name></person-group>
<year>2001</year>
<article-title>Cardiovascular protection and blood pressure reduction: a
meta-analysis.</article-title>
<source>The Lancet Volume</source>
<volume>358</volume>
<fpage>1305</fpage>
<lpage>1315</lpage>
<comment>[Erratum appears in Lancet 2002 Jan
26;359(9303):360]</comment>
</element-citation></ref><ref id="pone.0019857-Malekzadeh1"><label>33</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Malekzadeh</surname><given-names>F</given-names></name><name><surname>Marshall</surname><given-names>T</given-names></name><name><surname>Pourshams</surname><given-names>A</given-names></name><name><surname>Gharravi</surname><given-names>M</given-names></name><name><surname>Aslani</surname><given-names>A</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>A pilot double-blind randomised placebocontrolled trial of the
effects of fixed-dose combination therapy (&#x02018;polypill&#x02019;) on
cardiovascular risk factors.</article-title>
<source>International Journal of Clinical Practise</source>
<volume>64</volume>
<fpage>1220</fpage>
<lpage>1227</lpage>
</element-citation></ref><ref id="pone.0019857-Soliman1"><label>34</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Soliman</surname><given-names>E</given-names></name><name><surname>Mendis</surname><given-names>S</given-names></name><name><surname>Dissanayake</surname><given-names>W</given-names></name><name><surname>Somasundaram</surname><given-names>N</given-names></name><name><surname>Gunaratne</surname><given-names>P</given-names></name><etal/></person-group>
<year>2011</year>
<article-title>A Polypill for primary prevention of cardiovascular disease: A
feasibility study of the World Health Organization.</article-title>
<source>Trials</source>
<volume>12</volume>
<fpage>3</fpage>
<pub-id pub-id-type="pmid">21205325</pub-id></element-citation></ref><ref id="pone.0019857-Jackson3"><label>35</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jackson</surname><given-names>R</given-names></name><name><surname>Lawes</surname><given-names>C</given-names></name><name><surname>Bennett</surname><given-names>D</given-names></name><name><surname>Milne</surname><given-names>R</given-names></name><name><surname>Rodgers</surname><given-names>A</given-names></name></person-group>
<year>2005</year>
<article-title>Treatment with drugs to lower blood pressure and blood
cholesterol based on an individual's absolute cardiovascular
risk.</article-title>
<source>Lancet</source>
<volume>365</volume>
<fpage>434</fpage>
<lpage>441</lpage>
<pub-id pub-id-type="pmid">15680460</pub-id></element-citation></ref><ref id="pone.0019857-Thompson1"><label>36</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thompson</surname><given-names>AM</given-names></name><name><surname>Hu</surname><given-names>T</given-names></name><name><surname>Eshelbrenner</surname><given-names>CL</given-names></name><name><surname>Reynolds</surname><given-names>K</given-names></name><name><surname>He</surname><given-names>J</given-names></name><etal/></person-group>
<year>2011</year>
<article-title>Antihypertensive treatment and secondary prevention of
cardiovascular disease events among persons without hypertension: a
meta-analysis.</article-title>
<source>JAMA</source>
<volume>305</volume>
<fpage>913</fpage>
<lpage>922</lpage>
<pub-id pub-id-type="pmid">21364140</pub-id></element-citation></ref><ref id="pone.0019857-DeBacker1"><label>37</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Backer</surname><given-names>G</given-names></name><name><surname>Ambrosioni</surname><given-names>E</given-names></name><name><surname>Borch-Johnsen</surname><given-names>K</given-names></name><name><surname>Brotons</surname><given-names>C</given-names></name><name><surname>Cifkova</surname><given-names>R</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>European guidelines on cardiovascular disease prevention in
clinical practice: Third Joint Task Force of European and other Societies on
Cardiovascular Disease Prevention in Clinical Practice (constituted by
representatives of eight societies and by invited experts).</article-title>
<source>European Journal of Cardiovascular Prevention &#x00026;
Rehabilitation</source>
<volume>10</volume>
<fpage>S1</fpage>
<lpage>S78</lpage>
<pub-id pub-id-type="pmid">14555889</pub-id></element-citation></ref><ref id="pone.0019857-Wells1"><label>38</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wells</surname><given-names>S</given-names></name><name><surname>Broad</surname><given-names>J</given-names></name><name><surname>Jackson</surname><given-names>R</given-names></name><name><surname>Wells</surname><given-names>S</given-names></name><name><surname>Broad</surname><given-names>J</given-names></name><etal/></person-group>
<year>2006</year>
<article-title>Estimated prevalence of cardiovascular disease and distribution
of cardiovascular risk in New Zealanders: data for healthcare planners,
funders, and providers.</article-title>
<source>New Zealand Medical Journal</source>
<volume>119</volume>
<fpage>U1935</fpage>
<pub-id pub-id-type="pmid">16633394</pub-id></element-citation></ref><ref id="pone.0019857-Kotseva1"><label>39</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kotseva</surname><given-names>K</given-names></name><name><surname>Wood</surname><given-names>D</given-names></name><name><surname>De Backer</surname><given-names>G</given-names></name><name><surname>De Bacquer</surname><given-names>D</given-names></name><name><surname>Py&#x000f6;r&#x000e4;l&#x000e4;</surname><given-names>K</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Cardiovascular prevention guidelines in daily practice: a
comparison of EUROASPIRE I, II, and III surveys in eight European
countries.</article-title>
<source>The Lancet</source>
<volume>373</volume>
<fpage>929</fpage>
<lpage>940</lpage>
</element-citation></ref><ref id="pone.0019857-Webster1"><label>40</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Webster</surname><given-names>RJ</given-names></name><name><surname>Heeley</surname><given-names>EL</given-names></name><name><surname>Peiris</surname><given-names>DP</given-names></name><name><surname>Bayram</surname><given-names>C</given-names></name><name><surname>Cass</surname><given-names>A</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Gaps in cardiovascular disease risk management in Australian
general practice.</article-title>
<source>Medical Journal of Australia</source>
<volume>191</volume>
<fpage>324</fpage>
<lpage>329</lpage>
<pub-id pub-id-type="pmid">19769555</pub-id></element-citation></ref><ref id="pone.0019857-Kumar1"><label>41</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Fonarow</surname><given-names>GC</given-names></name><name><surname>Eagle</surname><given-names>KA</given-names></name><name><surname>Hirsch</surname><given-names>AT</given-names></name><name><surname>Califf</surname><given-names>RM</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Regional and practice variation in adherence to guideline
recommendations for secondary and primary prevention among outpatients with
atherothrombosis or risk factors in the United States: a report from the
REACH Registry.</article-title>
<source>Critical Pathways in Cardiology: A Journal of Evidence-Based
Medicine</source>
<volume>8</volume>
<fpage>104</fpage>
<lpage>111</lpage>
</element-citation></ref><ref id="pone.0019857-World3"><label>42</label><element-citation publication-type="book">
<collab>World Health Organisation</collab>
<year>2003</year>
<article-title>Adherence to long-term therapies.</article-title>
<source>Evidence for action</source>
<publisher-loc>Geneva</publisher-loc>
<publisher-name>WHO</publisher-name>
</element-citation></ref><ref id="pone.0019857-Beaglehole1"><label>43</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beaglehole</surname><given-names>R</given-names></name><name><surname>Ebrahim</surname><given-names>S</given-names></name><name><surname>Reddy</surname><given-names>S</given-names></name><name><surname>Vo&#x000fb;te</surname><given-names>J</given-names></name><name><surname>Leeder</surname><given-names>S.</given-names></name></person-group>
<article-title>Prevention of chronic diseases: a call to action.</article-title>
<source>The Lancent</source>
<volume>370</volume>
<fpage>2152</fpage>
<lpage>2157</lpage>
</element-citation></ref><ref id="pone.0019857-Mendis1"><label>44</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mendis</surname><given-names>S</given-names></name><name><surname>Abegunde</surname><given-names>D</given-names></name><name><surname>S</surname><given-names>Y</given-names></name><name><surname>Ebrahim</surname><given-names>S</given-names></name><name><surname>Shaper</surname><given-names>G</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>WHO study on Prevention of REcurrences of Myocardial Infarction
and StrokE (WHO-PREMISE).</article-title>
<source>Bulletin of the World Health Organization</source>
<volume>83</volume>
<fpage>820</fpage>
<lpage>828</lpage>
<pub-id pub-id-type="pmid">16302038</pub-id></element-citation></ref><ref id="pone.0019857-Sharma1"><label>45</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sharma</surname><given-names>KK</given-names></name><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Agrawal</surname><given-names>A</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name><name><surname>Kasliwal</surname><given-names>A</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Low use of statins and other coronary secondary prevention
therapies in primary and secondary care in India.</article-title>
<source>Vasc Health Risk Manag</source>
<volume>5</volume>
<fpage>1007</fpage>
<lpage>1014</lpage>
<pub-id pub-id-type="pmid">19997570</pub-id></element-citation></ref><ref id="pone.0019857-Selak1"><label>46</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Selak</surname><given-names>V</given-names></name><name><surname>Rafter</surname><given-names>N</given-names></name><name><surname>Parag</surname><given-names>V</given-names></name><name><surname>Tomlin</surname><given-names>A</given-names></name><name><surname>Hoorn</surname><given-names>SV</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Cardiovascular treatment gaps: Closing, but
slowly.</article-title>
<source>New Zealand Medical Journal</source>
<volume>122</volume>
<fpage>41</fpage>
<lpage>49</lpage>
<pub-id pub-id-type="pmid">19966877</pub-id></element-citation></ref><ref id="pone.0019857-Murray1"><label>47</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Murray</surname><given-names>CJL</given-names></name><name><surname>Lauer</surname><given-names>JA</given-names></name><name><surname>Hutubessy</surname><given-names>RCW</given-names></name><name><surname>Niessen</surname><given-names>L</given-names></name><name><surname>Tomijima</surname><given-names>N</given-names></name><etal/></person-group>
<year>2003</year>
<article-title>Effectiveness and costs of interventions to lower systolic blood
pressure and cholesterol: a global and regional analysis on reduction of
cardiovascular-disease risk.</article-title>
<source>Lancet</source>
<volume>361</volume>
<fpage>717</fpage>
<lpage>725</lpage>
<pub-id pub-id-type="pmid">12620735</pub-id></element-citation></ref><ref id="pone.0019857-Gaziano1"><label>48</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gaziano</surname><given-names>TA</given-names></name><name><surname>Opie</surname><given-names>LH</given-names></name><name><surname>Weinstein</surname><given-names>MC</given-names></name></person-group>
<year>2006</year>
<article-title>Cardiovascular disease prevention with a multidrug regimen in the
developing world: a cost-effectiveness analysis.</article-title>
<source>Lancet</source>
<volume>368</volume>
<fpage>679</fpage>
<lpage>686</lpage>
<pub-id pub-id-type="pmid">16920473</pub-id></element-citation></ref><ref id="pone.0019857-Goldberg1"><label>49</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>RJ</given-names></name><name><surname>Currie</surname><given-names>K</given-names></name><name><surname>White</surname><given-names>K</given-names></name><name><surname>Brieger</surname><given-names>D</given-names></name><name><surname>Steg</surname><given-names>PG</given-names></name><etal/></person-group>
<year>2004</year>
<article-title>Six-month outcomes in a multinational registry of patients
hospitalized with an acute coronary syndrome (The Global Registry of Acute
Coronary Events [GRACE]).</article-title>
<source>The American journal of cardiology</source>
<volume>93</volume>
<fpage>288</fpage>
<lpage>293</lpage>
<pub-id pub-id-type="pmid">14759376</pub-id></element-citation></ref><ref id="pone.0019857-Lim1"><label>50</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lim</surname><given-names>S</given-names></name><name><surname>Gaziano</surname><given-names>TA</given-names></name><name><surname>Gakidou</surname><given-names>E</given-names></name><name><surname>Srinath Reddy</surname><given-names>K</given-names></name><name><surname>Farzadfar</surname><given-names>F</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Prevention of cardiovascular disease in high-risk individuals in
low-income and middle-income countries: health effects and
costs.</article-title>
<source>Lancet</source>
<volume>370</volume>
<fpage>2054</fpage>
<lpage>2062</lpage>
<pub-id pub-id-type="pmid">18063025</pub-id></element-citation></ref><ref id="pone.0019857-Longstreth1"><label>51</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Longstreth</surname><given-names>GF</given-names></name></person-group>
<year>1995</year>
<article-title>Epidemiology of hospitalization for acute upper gastrointestinal
hemorrhage: a population-based study.</article-title>
<source>American Journal of Gastroenterology</source>
<volume>90</volume>
<fpage>206</fpage>
<lpage>210</lpage>
<pub-id pub-id-type="pmid">7847286</pub-id></element-citation></ref><ref id="pone.0019857-Lewis1"><label>52</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lewis</surname><given-names>JD</given-names></name><name><surname>Bilker</surname><given-names>WB</given-names></name><name><surname>Brensinger</surname><given-names>C</given-names></name><name><surname>Farrar</surname><given-names>JT</given-names></name><name><surname>Strom</surname><given-names>BL</given-names></name></person-group>
<year>2002</year>
<article-title>Hospitalization and mortality rates from peptic ulcer disease and
GI bleeding in the 1990s: relationship to sales of nonsteroidal
anti-inflammatory drugs and acid suppression medications.</article-title>
<source>Am J Gastroenterol</source>
<volume>97</volume>
<fpage>2540</fpage>
<lpage>2549</lpage>
<pub-id pub-id-type="pmid">12385436</pub-id></element-citation></ref><ref id="pone.0019857-Fox1"><label>53</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fox</surname><given-names>KAA</given-names></name><name><surname>Steg</surname><given-names>PG</given-names></name><name><surname>Eagle</surname><given-names>KA</given-names></name><name><surname>Goodman</surname><given-names>SG</given-names></name><name><surname>Anderson</surname><given-names>FA</given-names></name><etal/></person-group>
<year>2007</year>
<article-title>Decline in rates of death and heart failure in acute coronary
syndromes, 1999-2006.</article-title>
<source>JAMA</source>
<volume>297</volume>
<fpage>1892</fpage>
<lpage>1900</lpage>
<pub-id pub-id-type="pmid">17473299</pub-id></element-citation></ref><ref id="pone.0019857-Law7"><label>54</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Law</surname><given-names>M</given-names></name><name><surname>Morris</surname><given-names>JK</given-names></name><name><surname>Jordan</surname><given-names>R</given-names></name><name><surname>Wald</surname><given-names>N</given-names></name><name><surname>Law</surname><given-names>M</given-names></name><etal/></person-group>
<year>2005</year>
<article-title>Headaches and the treatment of blood pressure: results from a
meta-analysis of 94 randomized placebo-controlled trials with 24,000
participants.</article-title>
<source>Circulation</source>
<volume>112</volume>
<fpage>2301</fpage>
<lpage>2306</lpage>
<pub-id pub-id-type="pmid">16216977</pub-id></element-citation></ref><ref id="pone.0019857-Law8"><label>55</label><element-citation publication-type="other">
<person-group person-group-type="author"><name><surname>Law</surname><given-names>M</given-names></name><name><surname>Wald</surname><given-names>N</given-names></name><name><surname>Morris</surname><given-names>J.</given-names></name></person-group>
<article-title>Lowering blood pressure to prevent myocardial infarction and
stroke: a new preventive strategy.</article-title>
<comment>[Review] [188 refs]</comment>
</element-citation></ref><ref id="pone.0019857-deGalan1"><label>56</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Galan</surname><given-names>BE</given-names></name><name><surname>Perkovic</surname><given-names>V</given-names></name><name><surname>Ninomiya</surname><given-names>T</given-names></name><name><surname>Pillai</surname><given-names>A</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><etal/></person-group>
<year>2009</year>
<article-title>Lowering blood pressure reduces renal events in type 2
diabetes.</article-title>
<source>Journal of the American Society of Nephrology</source>
<volume>20</volume>
<fpage>883</fpage>
<lpage>892</lpage>
<pub-id pub-id-type="pmid">19225038</pub-id></element-citation></ref><ref id="pone.0019857-Antiplatelet1"><label>57</label><element-citation publication-type="journal">
<collab>Antiplatelet Trialists'Collaboration</collab>
<year>1994</year>
<article-title>Collaborative overview of randomised trials of antiplatelet
therapy&#x02013;III: Reduction in venous thrombosis and pulmonary embolism by
antiplatelet prophylaxis among surgical and medical
patients.</article-title>
<source>British Medical Journal</source>
<volume>308</volume>
<fpage>235</fpage>
<lpage>246</lpage>
<pub-id pub-id-type="pmid">8054013</pub-id></element-citation></ref><ref id="pone.0019857-Andraws1"><label>58</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Andraws</surname><given-names>R</given-names></name><name><surname>Brown</surname><given-names>DL</given-names></name><name><surname>Andraws</surname><given-names>R</given-names></name><name><surname>Brown</surname><given-names>DL</given-names></name></person-group>
<year>2007</year>
<article-title>Effect of inhibition of the renin-angiotensin system on
development of type 2 diabetes mellitus (meta-analysis of randomized
trials).</article-title>
<source>American Journal of Cardiology</source>
<volume>99</volume>
<fpage>1006</fpage>
<lpage>1012</lpage>
<pub-id pub-id-type="pmid">17398202</pub-id></element-citation></ref><ref id="pone.0019857-Law9"><label>59</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Law</surname><given-names>M</given-names></name><name><surname>Wald</surname><given-names>N</given-names></name><name><surname>Morris</surname><given-names>J</given-names></name></person-group>
<year>2003</year>
<article-title>Lowering blood pressure to prevent myocardial infarction and
stroke: a new preventive strategy.</article-title>
<source>Health Technology Assessment (Winchester, England)</source>
<volume>7</volume>
<fpage>1</fpage>
<lpage>94</lpage>
</element-citation></ref><ref id="pone.0019857-Sattar1"><label>60</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sattar</surname><given-names>N</given-names></name><name><surname>Preiss</surname><given-names>D</given-names></name><name><surname>Murray</surname><given-names>HM</given-names></name><name><surname>Welsh</surname><given-names>P</given-names></name><name><surname>Buckley</surname><given-names>BM</given-names></name><etal/></person-group>
<year>2010</year>
<article-title>Statins and risk of incident diabetes: a collaborative
meta-analysis of randomised statin trials.</article-title>
<source>The Lancet</source>
<volume>375</volume>
<fpage>735</fpage>
<lpage>742</lpage>
</element-citation></ref><ref id="pone.0019857-Law10"><label>61</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Law</surname><given-names>MR</given-names></name><name><surname>Rudnicka</surname><given-names>AR</given-names></name></person-group>
<year>2006</year>
<article-title>Statin Safety: A Systematic Review.</article-title>
<source>The American Journal of Cardiology</source>
<volume>97</volume>
<fpage>S52</fpage>
<lpage>S60</lpage>
</element-citation></ref><ref id="pone.0019857-Rothwell1"><label>62</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rothwell</surname><given-names>PM</given-names></name><name><surname>Fowkes</surname><given-names>FGR</given-names></name><name><surname>Belch</surname><given-names>JFF</given-names></name><name><surname>Ogawa</surname><given-names>H</given-names></name><name><surname>Warlow</surname><given-names>CP</given-names></name><etal/></person-group>
<year>2011</year>
<article-title>Effect of daily aspirin on long-term risk of death due to cancer:
analysis of individual patient data from randomised trials.</article-title>
<source>The Lancet</source>
<volume>377</volume>
<fpage>31</fpage>
<lpage>41</lpage>
</element-citation></ref></ref-list></back></article>